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ABSTRACT 
Chemotherapy is a widely used treatment for cancer, with significant side effects 
including cognitive impairments that affect patients’ quality of life.  Red raspberries are 
known to inhibit growth of cancer cells with recent research suggesting the ability to also 
protect neurons.  If this protective ability can be confirmed, red raspberry may emerge as 
a promising natural intervention for cognitive impairments associated with 
chemotherapy.  In addition, many studies have linked cognitive functions to epigenetic 
mechanisms postulating that transient reprogramming of epigenetic mechanisms, such as 
DNA methylation, is required for some basic neuronal/cognitive functions.   
The objective of this dissertation is to study the effects of in vitro digested and in 
vivo human metabolized red raspberry on doxorubicin chemotherapy initiated 
neurotoxicity in nerve growth factor induced PC12 pheochromocytoma neuronal cells, 
and explore the underlying epigenetic DNA methylation changes associated with this 
process. 
Primary results are summarized as: 1) minute amounts, as low as 0.001µM of 
doxorubicin reduced the metabolic activity of nerve growth factor induced PC12 
neuronal cells, exibiting neurotoxicity; 2) in vitro digested red raspberry counteracted the 
toxic effects of doxorubicin chemotherapy on the metabolic activity and neurite growth 
of nerve growth factor induced PC12 neuronal cells; 3) participants’ plasma after red 
raspberry consumption showed positive effects on metabolic activity of nerve growth 
factor induced PC12 neuronal cells treated with doxorubicin chemotherapy; 4) DNA 
methylation pattern of FOS gene for nerve growth factor induced PC12 neuronal cells 
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treated with doxorubicin was different from the control and in vitro digested red 
raspberry treated cells.  Possible explanations for these results are discussed. 
This dissertation research contributes to a better understanding of neurotoxicity due 
to doxorubicin chemotherapy and the neuroprotection of in vitro digested and in vivo 
human metabolized red raspberry at the cellular and epigenetic level.  This work provides 
evidence for future preliminary clinical trials investigating natural red raspberry 
consumption as an intervention for cognitive impairments in cancer patients receiving 
doxorubicin chemotherapy. 
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CHAPTER ONE   INTRODUCTION 
1.1 Motivation and Objectives 
Studies show that chemotherapy may initiate or potentiate cognitive decline 
(“chemobrain”) experienced by patients with a variety of types of cancer (Ahles, Aaykin, 
& Furstenberg, 2002; Brezden, Phillips, Abdolell, Bunston, & Tannock, 2000; Downie, 
Mar Fan, Houede-Tchen, Yi, & Tannock, 2006; Jansen, Cooper, Dodd, & Miaskowski, 
2010; Schagen, van Dam, Muller, Boogerd, Lindeboom, & Bruning, 1999; Shilling, 
Jenkins, Morries, Deutsch, & Bloomfield, 2005; Wefel, Lenzi, Theriault, Buzdar, 
Cruickshank, & Meyers, 2004).  Types of decline may include decline in attention, 
executive function, processing speed, motor function, learning and memory (Ahles & 
Saykin, 2007).  The incidence of chemotherapy induced cognitive decline in cancer 
patients is reported to be from16% to 75% depending on different study population, 
chemotherapy regimens and study methodology (Calvio, Peugeot, Bruns, Todd, & 
Feuerstein, 2010).  The cognitive changes may persist following completion of treatment 
and can significantly impact both the short-term and long-term quality of life for cancer 
survivors (Ahles & Saykin, 2007; Ahles et al., 2002).  Younger survivors face the 
challenge of maintaining competitiveness in their school and jobs, while older survivors 
may have increased susceptibility to memory loss resulting in an impaired ability to self-
manage (Nelson, Nandy, & Roth, 2007).  Pharmacologic treatments for chemotherapy 
induced cognitive decline have been explored.  One of these is methylphenidate.  
However, there are serious side effects associated with this drug including loss of 
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appetite, headache, hair loss, depression, seizures and anemia (Thompson et al., 2001).  A 
natural intervention with fewer side effects would be well received. 
The published evidence from our lab and other research groups indicates that berries  
could sensitize tumor cells to chemotherapeutic agents in vitro and in vivo (Aziz et al., 
2002; Chen, Hwang, Rose, Nines, & Stone, 2006a; Duthie, 2007; Kresty et al., 2006; 
Tate, Kuzmar, Smith, Wedge, & Larcom, 2003; Lu et al., 2006; Seeram et al., 2006; Tate, 
Kuzmar, Smith, & Wedge, 2001; Xue et al., 2001).  Some studies have linked multiple 
varieties of berries to neuro-protection in vitro and in animal models (Barros, Amaral, & 
Ramirez, 2006; Bastianetto, Dumont, Han, & Quirion, 2009; Fortalezas et al., 2010; 
Joseph, Shukitt-Hale, & Willis, 2009; Kang, Hur, Kim, Ryu, & Kim, 2006).  The known 
constituents in berries that exhibit neuro-protective effects are phenolic molecules such as 
anthocyanins, flavonols, flavanols, proan-thocyanidins, ellagitannins, and phenolic acids 
(Barros et al., 2006; Bastianetto et al., 2009; Fortalezas et al., 2010; Joseph et al., 2009; 
Kang et al., 2006; Seeram, 2008).  Different types of berries have different combinations 
of the noted constituents that exhibit various neuro-protective properties.  Although the 
extracts of berries (mostly antioxidants) perform well in some aspects, the natural 
combination of all the constituents may have the most beneficial effects and least side 
effects (Anttonen & Karjalainen, 2005; Aruoma, Bahorun, & Jen, 2003; de Ancos, 
Gonzales, & Cano, 2000; Joseph et al., 2009). 
In addition, many studies have linked cognitive function to epigenetic mechanisms 
postulating that transient reprogramming of epigenetic codes, such as DNA methylation 
and histone modifications, is required for some basic cognitive functions such as memory 
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consolidation (Feng et al., 2010; Levenson et al., 2006; Miller & Sweatt, 2007; Lubin et 
al., 2008; Korzus, Rosenfeld, & Mayford, 2004; Miller, Campbell & Sweatt, 2008).  As 
shown in Figure 1.1, folate, another important natural constituent in berries, is an 
indispensable element in the pathway of epigenetic methylation, contributing to the 
provision of methyl groups to S-adenosylmethionine (SAM) for use in methylation (Lu, 
Wylie, Andrews, & Tollefshol, 2003).  Therefore, the intake of folate influences the 
availability of methyl groups for DNA or histone methylation.  When methylated, DNA 
or histones will recruit different chromatin remodeling complexes to promote the 
compacting or opening of chromatin in order to regulate gene transcription.  The 
activation and silencing of genes, such as EGR1, FOS and BDNF, important in neuronal 
functions, can lead to changes in cognitive functions (Aid, Kazantseva, Piirsoo, & 
Timmusk, 2007; Bozon, Davis, & Laroche, 2002; Hu et al., 1994). 
In summary, many cancer patients experience cognitive decline after treatment with 
certain types of chemotherapy (Schagen et al., 1999; Brezden et al., 2000; Ahles et al., 
2002; Wefel et al., 2004; Shilling et al., 2005; Downie et al., 2006; Jansen et al., 2010).  
Epigenetic modifications have been shown to be a key factor in cognitive functions 
especially memory formation (Feng et al., 2010; Levenson et al., 2006; Miller & Sweatt, 
2007; Lubin et al., 2008; Korzus et al., 2004; Miller et al., 2008).  Berries have been 
shown to involve in epigenetic modifications (Lu et al., 2003), protect neurons (Joseph et 
al., 2009; Barros et al., 2006; Bastianetto et al., 2009; Fortalezas et al., 2010; Kang et al., 
2006; Seeram, 2008), and inhibit cancer progression (Seeram et al., 2006; Tate et al., 
 4 
2003; Wedge et al., 2001; Xue et al., 2001; Kresty et al., 2006; Aziz et al., 2002; Duthie 
2007; Chen et al., 2006a; Lu et al., 2006).  
Based on the above reviewed research, the over-reaching research question focuses 
on whether red raspberry (RR) can prevent cognitive decline experienced by cancer 
patients receiving chemotherapy.  To provide the basic scientific foundation necessary to 
answer this question, the objective of this dissertation is to study the effects of in vitro 
digested RR and in vivo human metabolized RR on doxorubicin (DOX) chemotherapy 
initiated neurotoxicity, and explore the underlying epigenetic DNA methylation changes 
associated with this process. The model system was nerve growth factor (NGF) induced 
pheochromocytoma (PC12) neuronal cells (NGF induced PC12 neuronal cells will be 
designated as ‘PC12 neuronal cells’).  In order to achieve the objective, the following 
specific aims are addressed: 
Identify the effects of DOX chemotherapy on the metabolic activity of PC12 
neuronal cells; 
Identify the effects of in vitro digested RR on the metabolic activity of PC12 
neuronal cells; 
Describe the effects of in vitro digested RR on the metabolic activity of DOX 
chemotherapy treated PC12 neuronal cells; 
Describe the effects of in vitro digested RR on the neurite growth of DOX 
chemotherapy treated PC12 neuronal cells; 
Compare the effects of human plasma collected from healthy donors prior to and 
after RR consumption on DOX treated PC12 neuronal cells; and 
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Identify the effects of DOX, in vitro digested RR and their combination treatments 
on the DNA methylation of PC12 neuronal cells. 
 
1.2 Literature Review 
1.2.1 Chemotherapy Induced Cognitive Decline and Neurotoxicity 
Many cancer patients experience cognitive decline associated with chemotherapy 
treatments.  For some of these patients, cognitive function declines subtly and often 
improves after ceasing chemotherapy; however, for a subset of cancer survivors, the 
symptoms persist and significantly impact their ability to function and their quality of life 
(Vardy, Wefel, Ahles, & Tannock, & Schagen, 2008). 
A number of studies have looked at the cognitive decline in cancer patients 
receiving chemotherapy (Ahles et al., 2002; Brezden et al., 2000; Downie et al., 2006; 
Jansen et al., 2010; Schagen, Muller, Boogerd, Mellenbergh, & van Dam, 2006; Schagen 
et al., 1999; Shilling et al., 2005; Tannock, Ahles, Ganz, & van Dam, 2004; Vardy et al., 
2006; Wefel et al., 2004; Vardy & Tannock, 2007).  However, the methodological 
limitations and variations of these studies restricted the validity and generalization of 
results.  Specifically, selection of controls, selection of cognitive batteries, 
identification/measurement of confounding variables, and measurement intervals are 
some of the key factors that differed in the research designs. 
Studies were performed using different control groups (Schagen et al., 2006; 
Shilling et al., 2005).  The best controls were those that closely resembled the treatment 
groups, but only differed in independent variables and some to-be-measured confounding 
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variables.  For example, to look at cognitive decline associated with chemotherapy, the 
control group should be cancer patients who are not undergoing chemotherapy.  Healthy 
controls should also be included if possible.   
The longitudinal study by Schagen et al. (2006) compared the cognitive changes for 
four groups of patients: those with high dose chemotherapy with cyclophosphamide, 
thiotepa, and carboplatin (N = 39), standard dose chemotherapy with 5-fluorouracil, 
epirubicin, and cyclophosphamide (N = 28), no chemotherapy (N = 57) and healthy 
volunteers (N = 60).  The neuropsychological examination consisted of 10 tests and 24 
indices covering tests such as working-verbal-visual memory, attention, and executive 
function.  The researchers identified that patients receiving high dose chemotherapy had 
significantly more cognitive decline than healthy controls (p < 0.02) while the other 
groups showed a non-significant decline trend compared with healthy controls (p = 0.2).  
Though this study did not show statistically significant results of cognitive decline for 
those receiving standard chemotherapy doses, the clinical relevance indicated in a 
downward trend should not be ignored.   
A study by Shilling et al. (2005) evaluated three groups of patients: those to receive 
different chemotherapy regimens (N = 85), those to receive hormone treatment (N = 43), 
and a group of healthy controls (N = 49).  Pre-tests, 6-month post-tests and 12-month 
post-tests results were obtained.  There were no significant differences in overall 
cognitive function including visual-working memory, intelligence, and processing speed 
among groups.  Nevertheless, a clinically relevant trend of cognitive decline was 
observed in all groups. Interestingly, the hormone group showed the largest decline of 
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26%, while the chemotherapy group was next with 20%.  As anticipated, the healthy 
control group showed the least decline of 18%. 
Studies were performed using different cognitive batteries.  The most discrepancies 
of cognitive batteries were found between subjective self-report assessments and 
objective neuropsychological assessments.  To emphasize this problem, Downie et al. 
(2006) compared the assessments using self-report questionnaires and a researcher-
administered screen of cognitive functions.  Of participants whose memory was measured 
by the researcher-administered neuropsychological assessment, 48% had difficulties with 
memory.  Ninety-five percent of participants who self-reported their experiences noted 
memory problems.  Two other studies (Schagen et al., 1999; Vardy et al., 2006) indicated 
the self-reported incidence was more associated with affective change (emotional change, 
anxiety and depression) than objective impairment.  However, it was noted that self-
reporting can capture some aspects that objective tests miss, such as ability to multitask 
or daily work under relevant conditions (Tannock et al., 2004).  Evaluating cognitive 
decline is difficult because of the following reasons.   First, there are numerous cognitive 
batteries that can be used for measurement.  Both individual domain score, evaluating 
one of the cognitive function domains such as processing speed, attention, memory 
retrieval, executive function, and multiple domain scores can be used in a study.  In 
addition, there are different ways to administer the cognitive tests.  For example, tests can 
be researcher-directed or self-directed, paper-based or computer-based.  But the 
differences in communication of instructions, stimulus presentation, and response format 
may yield significant differences in test performance (Wild, Howieson, Webbe, Seelye, 
 8 
& Kaye, 2008).  There are also numerous ways to define abnormal performance of 
cognitive functions since different cut-off points for detecting impairments can be applied 
(Vardy et al., 2008).  Succinctly, there is not a standardized assessment guideline and 
methodology that can be used. 
Studies were performed measuring different confounding variables.  Brezden et al. 
(2000) investigated differences in cognitive function between breast cancer patients 
treated with standard-dose adjuvant chemotherapy (either cyclophosphamide, epirubicin, 
and fluorouracil, or cyclophosphamide, methotrexate, and fluorouracil) versus healthy 
controls.  The High Sensitivity Cognitive Screen and the Profile of Mood States (POMS) 
tools were used to assess memory, language, visual-motor, spatial, attention, 
concentration, self-regulation, planning and mood of the participants.  Memory domains 
were observed to be different between the treatment group and healthy controls (p = 
0.024), suggesting impairment in memory domains for patients receiving chemotherapy.  
However, besides mood change, other possible confounding variables such as pre-
existing cognitive differences, fatigue, anxiety, depression, stress, hormone levels, and 
other mediators were not considered.  Ahles and colleagues (2002) compared the 
neuropsychological functions of long-term survivors of breast cancer and lymphoma who 
were 5 years post-diagnosis, not presently receiving cancer treatments, and disease-free.  
Scores of participants who had been treated with standard-dose systemic chemotherapy 
regimens (N = 35) were compared with those of participants who had been treated with 
local therapy only (N = 35).  Controlling for age, education and some psychological 
factors including depression, anxiety and fatigue (by Center for Epidemiological Study-
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Depression, Spielberger State-Trait Anxiety Inventory, and Fatigue Symptom Inventory), 
the study revealed that survivors who had undergone systemic chemotherapy scored 
significantly lower on the battery of neuropsychological tests (p < 0.04), particularly in 
the domains of verbal memory (p < 0.01) and self-report working memory (p < 0.02).  A 
lack of pre-test of cognitive functions was identified as a study limitation, since there was 
a possibility that some patients may have scored above normal and other patients may 
have scored below normal before treatment, thus skewing the outcome of the research. 
Many other studies on cognitive decline in cancer patients who have received 
chemotherapy were completed without a pre-test.  One study illustrated the need for 
inclusion of pre-tests.  Wefel et al. (2004) used comprehensive neuropsychological 
evaluation to assess women with breast cancer (N = 84) prior to receiving adjuvant 
therapy for non-metastatic primary breast carcinoma.  The researchers found that prior to 
chemotherapy, 25% of the patients had impaired memory, a significant finding when 
compared to normative expectations.  These results emphasize the importance to employ 
study designs that incorporate pre-chemotherapy baseline assessments in order to 
accurately measure chemotherapy-induced cognitive decline.  In addition, the timing of 
pre-tests is also important.  The only realistic time is after diagnosis and before any 
treatment such as surgery or hormonal medication.  However, the stress related to a new 
life-threatening diagnosis or life- altering surgery can be a possible confounding variable, 
and should be considered (Vardy & Tannock, 2007). 
As shown in Figure 1.2, the mechanisms that cause the disruption of cognitive 
function by chemotherapy remain unknown. However, there are contributing factors that 
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are associated with this process, such as direct neurotoxic effects, genetic susceptibility, 
oxidative stress, DNA damage, cytokine and hormone changes. 
First, chemotherapy is a known factor that can directly cause neuronal cell death or 
reduced proliferation of brain neurons.  Dietrich et al. (2006) administered the three 
mainstream chemotherapeutic agents carmustine (BCNU), cisplatin, and cytosine 
arabinoside (cytarabine) in vitro to multiple cell lines and in vivo to CBA mice.  They 
found these agents are associated with increased cell death and decreased cell division in 
the subventricular zone, in the dentate gyrus of the hippocampus and in the corpus 
callosum of the central nervous system (CNS) in mice. 
Although chemotherapeutic agents are generally assumed to be unable to cross the 
blood-brain barrier, more and more chemotherapeutic agents have been reported to cross 
the blood-brain barrier in standard doses including methotrexate, cisplatin, cytarabine, 
ifosfamide, procarbazine, temozolomide, carmustine, lomustine (Wilkes & Barton-Burke, 
2007; Myers, Piercem & Pazdernik, 2008).  The mechanisms of how this movement 
occurs remain almost unknown except for one plausible explanation: genetic 
polymorphisms or mutations in drug transporters in blood-brain barrier.  For example, P-
glycoprotein, encoded by the multidrug resistance1 (MDR1) gene and expressed in the 
capillary endothelial cells in the blood-brain barrier, is responsible for keeping 
unwelcomed drugs out of brain.  Several polymorphisms of the MDR1 gene have been 
identified that may influence the expression and functions of this guard keeper 
(Jamroziak et al., 2004; Ahles & Saykin, 2007).  Genetic polymorphisms or mutations in 
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drug transporters in blood-brain barrier can also explain the phenomenon that not all 
patients treated with the same chemotherapy are subject to cognitive decline. 
Second, genetic variability or mutations in brain plasticity genes and 
neurotransmitter genes may account for the long-term cognitive changes in chemotherapy 
treated cancer patients.  For example, people with the E4 allele for the gene that encodes 
apolipoprotein E (APOE), a glycolipoprotein in charge of neuronal repair and plasticity 
after injury, may not be easily recovered from any injury induced by detrimental agents 
(Morley & Montgomery, 2001).  That is, these patients will need more time to recover or 
even cannot recover from the cognitive injury.  Detrimental agents may include 
chemotherapy that crosses the blood-brain barrier, or any physiological change secondary 
to this type of cancer treatment. 
Third, chemotherapy has been associated with increased DNA damages, increased 
free radicals, and decreased antioxidant activities that can lead to oxidative stress, as 
observed in cancer patients who develop anemia as a side effect of chemotherapy (Kaya, 
2005; Ahles & Saykin, 2007).  There is some literature that relates oxidative stress and 
DNA damage to Alzheimer’s disease (AD), aging, and other types of cognitive 
impairments (Butterfield & Kanski, 2001; Butterfield & Lauderback, 2002; Butterfield, 
Perluigi & Sultana, 2006; Mariani, Polidori, Cherubini, & Mecocci, 2005; Poon, 
Calabrese, Calvani, & Butterfield, 2006).  Unlike genetic polymorphisms, oxidative 
stress and DNA damage are secondary physiological changes, due to physiological 
mechanisms of cancer, chemotherapy and / or the combination of both, which can affect 
cognition in patients with cancer. 
 12 
It has been reported that more pro-inflammatory cytokines are released in women 
with breast cancer than in women with a negative breast biopsy (Lyon, McCain, & 
Walter, 2008).  Pro-inflammatory cytokines are associated with cognitive decline and 
sickness behaviors. These primarily include fatigue, decreased social interaction, 
decreased concentration, decreased executive function, stress and depression.  The 
proposed mechanisms for cytokines to cross the blood-brain barrier and affect cognitive 
functions include active transport, penetration in areas with fenestrated junctions, binding 
to receptors inside the blood vessels to activate secondary messengers that enter brain, 
and activation of vagus nerve (Maier & Watkins, 1998; Myers et al., 2008; Maier & 
Watkins, 2003). 
There are other chemical messengers with the ability to pass through the blood-brain 
barrier such as steroid and thyroid hormones.  They pass through the blood-brain barrier 
by carrier-mediated transport or plasma protein-mediated transport (Pardridge, 1988).  
Reductions of chemical messengers like estrogen and testosterone have been reported to 
associate with cognitive decline in cancer patients (Galea, Kavaliers, & Ossenkopp, 1995; 
Salminen, Portin, Koskinen, Helenius, & Nurmi, 2004).   
Interestingly, most of the studies on chemo-brain were done on breast cancer 
patients.  One possibility is that women with breast cancer experience more hormone 
fluctuations, thus have higher susceptibility of cognitive changes.  First, many of the 
established risk factors of breast cancer are linked to estrogens, such as menarche, 
menopause, endogenous/exogenous estradiol, childbearing and breastfeeding (Key, 
Verkasalo, & Banks, 2001).  Second, chemotherapy can induce an early and abrupt 
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menopause that can also cause cognitive decline.  Once again, most breast cancer patients 
are women that are subject to this chemically induced menopause.  Third, tamoxifen and 
aromatase inhibitors, often administered for women with breast cancer, compete for 
estrogen receptors and cause reduced levels of estrogen hormones.  Finally, it has been 
reported that some cytokines are involved in regulation of estrogen in breast cancer 
patients with the release of cytokines leading to stimulation of estrogen synthesis 
(Purohit, Newman, & Reed, 2002).  Considering all of the above estrogenic factors, it is 
probable that women with breast cancer undergoing menopause during the treatment, or 
with an estrogen receptor positive (ER+) tumor therefore administered hormone receptor 
inhibitors, or confirmed to have physiological hormonal decline may have a higher risk of 
cognitive decline during chemotherapy treatment. 
Doxorubicin chemotherapy, specifically included in this dissertation study, was 
isolated from cultures of a mutant Streptomyces peucetius (Streptomyces peucetius 
caesius) in the Farmitalia Research Laboratories in 1967 (Arcamone, Cassinelli, 
DiMarco, & Gaetani 1967; Bonadonna, Monfardini, Lena, & Fossati-Bellani, 1969).  
Historically, DOX is one of the most widely used systematic treatments for all types of 
cancers including adult breast cancer, soft tissue sarcomas, aggressive lymphomas, and 
childhood solid tumours (Minotti, Menna, Salvatorelli, Cairo, & Gianni, 2004).  
Although DOX was not originally believed to cross the blood-brain barrier (Ohnishi et 
al., 1995), it is well documented that this chemotherapy can induce neurotoxicity in vitro 
and cognitive dysfunction in vivo (Freeman and Broshek, 2002; Konat, Kraszpulski, 
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James, Zhang, & Abraham, 2008; Lopes, Meisel, Dirnagl, Carvalho, & Bastos, 2008; 
Joshi et al., 2005; Meyers, 2000; Schagen et al., 2006; Tangpong et al., 2006). 
Recently, studies have linked epigenetic mechanisms to cognitive function.  It is 
postulated that transient reprogramming of epigenetic codes such as DNA methylation 
and histone modifications is required for some basic cognitive functions, especially 
memory formation.  The next section will review the literature which illustrates the 
possible epigenetic control of memory functions, thus emphasizing the possibility of the 
involvement of epigenetic modifications in chemotherapy induced cognitive decline and 
neurotoxicity. 
 
1.2.2 Epigenetics and Cognition 
Epigenetics was originally defined as “the study of how genotypes give rise to 
phenotypes through programmed changes during development (Waddington, 1942, p. 18-
19)” to describe the cell-to-cell phenotypic alterations during the development in a 
multicellular organism.  With the knowledge that all the cells in an organism share 
identical DNA sequences, but may remarkably differ in their phenotypic expressions, 
epigenetics was later defined as “nuclear inheritance that is not based on differences in 
DNA sequence (Holliday, 1994, p. 453)”.  Subsequently, several other definitions were 
developed, but without substantive changes or wide recognition (Allis, Jenuwein, 
Reinberg, & Caparros, 2006; Russo, Martienssen, & Riggs, 1996; Wu & Morries, 2001).  
In 2009, Berger and colleagues defined epigenetics as “the study of heritable changes in 
gene expression that do not involve coding sequence modifications” (Berger, Kouzarides, 
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Shiekhattar, & Shilatifard, 2009, p. 781).  This definition is comprehensive in that it 
includes other modifications besides chromatin patterning in the nucleus, such as RNA 
interference, leading scientists to a world of epigenetic possibilities (Volpe et al., 2002; 
Tchuikov et al., 2004; Lippman et al., 2004).  However, since epigenetic marks can be 
transient and are not necessarily heritable, especially for the post-mitotic neurons targeted 
in this dissertation, a less comprehensive and more appropriate definition of epigenetics 
will be used.  This definition states epigenetics is: “ the structural adaptation of 
chromosomal regions so as to register, signal or perpetuate altered activity states” (Bird, 
2007, p. 398). 
The evidence-based epigenetic mechanisms primarily include DNA methylation, 
histone acetylation, histone methylation, histone phosphorylation, histone ubiquitylation 
and RNA interference, all of which are interrelated.  Since little research has been done 
regarding the regulation of memory by other epigenetic mechanisms, this section of the 
literature review primarily focuses on the regulation of memory formation by DNA 
methylation and histone acetylation. 
As shown in Figure 1.3, DNA methylation occurs at the cytosine of 5’-cytosine 
guanine-3’ (CG) dinucleotides with SAM as the methyl donor and DNA 
methyltransferases (Dnmts) as the catalysts (Miranda & Jones, 2007).  These methylated 
cytosines (methylcytosines) occur on ~ 70-80% of CG dinucleotides throughout the 
genome (Attwood, Yung, & Richardson, 2002).  When DNA methylation occupies the 
spaces where transcriptional factors usually bind, the downstream gene is silenced and no 
gene product (protein) is produced. 
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Methylated DNA also recruits methylcytosine-binding proteins, and subsequently 
other proteins to contribute to the formation of condensed chromatin (heterochromatin as 
illustrated in Figure 1.4).  Heterochromatin may cause the silence of a neighborhood of 
genes, because the transcriptional factors may lose access to a segment of DNA once 
chromatin is condensed. 
As shown in Figure 1.4, heterochromatin can be relaxed by some of the histone 
modifications including the most investigated histone acetylation.  Histone acetylation 
involves the binding of acetyl groups to lysines in the tails of histones, which is catalyzed 
by histone acetyltransferases (HATs) and reversed by histone deacetylases (HDACs) 
(Levenson & Sweatt 2005).  Histone acetylation usually balances the positive charge on 
histone tails, reduces the interaction between positively charged histones and negatively 
charged DNA backbone, relaxes the chromatin structure so that the genes are more 
accessible to transcriptional factors for transcription (Shahbazian & Grunstein, 2007; 
Wade, Pruss, & Wloffe, 1997;Watson et al., 2007).  In addition, combinations of histone 
acetylation and other histone modifications including histone phosphorylation, 
methylation, ubiquitination and ADP-ribosylation, serve as a unique histone language 
that is read by other proteins, such as bromo-domain containing proteins, to bring about 
downstream events and regulate transcription (Annunziato & Hansen, 2000; Li et al., 
2008; Margueron, Trojer, & Reinberg, 2005; Strahl & Allis, 2000).  Recent research 
indicates epigenetic mechanisms such as DNA methylation and histone 
acetylation/deacetylation may be critical for the changes that underlie cognition 
especially learning and long-term memory. 
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Levenson and Sweatt et al. (2006) were the first to hypothesize that DNA 
methyltransferase activity regulates synaptic plasticity, the ability to change in strength of 
synaptic connections, in the central nervous system; therefore suggesting methylation as a 
potential epigenetic mechanism associated with long-term memory formation.  To test the 
hypothesis, the researchers used methylation inhibitors, zebularine and 5-aza-2-
deoxycytidine, to inhibit DNA methyltransferase activity in hippocampal areas and 
evaluated in slices from euthanized mice.  After the inhibition, it was noted the promoter 
regions of the memory promoting genes Reelin and brain-derived neurotrophic factor 
(BDNF) experienced rapid and dramatic decreases in DNA methylation (2006).  It is 
projected this process contributed to the failure of long-term potentiation (a type of 
synaptic plasticity) induction at hippocampal Schaffer collateral synapses that is 
implicated to be important in long-term memory consolidation. 
After the first in vitro evidence, Miller et al. (2007) implemented an in vivo study to 
carefully illustrate that DNA methylation is not only associated with, but crucial and 
necessary in long-term memory formation (Miller & Sweatt, 2007). For this experiment, 
researchers first induced a group of adult male rats (Sprague Dawley) with a contextual 
fear conditioning (CFC) test.  After sacrificing, the DNA methylation pattern of several 
genes in the hippocampus was analyzed.  Rapid methylation (transcriptional silencing) of 
the memory suppressor gene PP1, and demethylation (activation) of the memory 
promoting gene Reelin were found after CFC, but not prior to.  Second, these researchers 
randomly assigned another set of adult male Sprague Dawley rats into two groups.  In 
group one: the experimental rats received the training for the CFC test, then a combined 
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injection of DNA methyltransferase inhibitors, zebularine and 5-aza-2-deoxycytidine.  In 
group two: the control rats also received training for the CFC test, then an injection of 
placebo.  The performance in subsequent CFC tests was compared for both groups.  The 
researchers found that after blocking the DNA methyltransferase activity using DNA 
methyltransferase inhibitors, the rats “froze” less in the CFC test compared to their 
placebo counterparts, indicating a decrease in long-term memory.  Using similar 
methodology with the CFC and the same type of rats, these researchers found changes in 
methylation affected differential regulation of BDNF gene expression, together with 
alterations in chromatin structure, again indicating the critical role of DNA methylation 
in the formation of long-term memory (Lubin, Roth, & Sweatt, 2008). 
In 2010, a study by Feng et al. also illustrated that DNA methylation is required for 
long-term memory.  These researchers’ engineered DNA methyltransferase 1 and DNA 
methyltransferase 3a double conditional knockout (DKO) mice to determine if complete 
loss of gene expression of these two proteins in forebrain neurons would lead to abnormal 
memory function.  Results indicated a number of genes in forebrain neurons of these 
DKO mice had an abnormal methylation pattern, deregulated expression, causing deficits 
in the ability to learn and memorize.  A neuronal loss was not identified, but the neurons 
did appear smaller than those seen in the wild type mice (Feng et al., 2010). 
The association of DNA methylation and intellectual disability can be illustrated by 
fragile X syndrome (FXS).  As the most common inherited intellectual disability, 
approximately 1 in 4,000 males, FXS can be caused by hypermethylation of CGG repeats 
in the 5’ untranslated (UTR) region of the fragile X mental retardation gene (FMR1), 
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causing the absence of its product, fragile X mental retardation protein (FMRP) (Garber, 
Visootsak, & Warren, 2008; Godler et al., 2010).  Another research group reported that 
treatment of fragile X cell line by methylation inhibitor 5-aza-2-deoxycytidine can cause 
passive demethylation of the FMR1 gene promoter and reactivate the gene expression in 
vitro (Pietrobono et al., 2002). 
Compared to DNA methylation, there is more evidence indicating the importance of 
histone acetylation and deacetylation in learning and memory.  Although not the first to 
illustrate the effect of histone regulation in neuronal physiological changes, Levenson et 
al. were the first to test the regulation of memory and learning by histone acetylation in 
vivo.  These researchers used HDAC inhibitors, trichostatin A or sodium butyrate, to 
elevate the level of histone acetylation and found it enhanced long-term potentiation at 
Schaffer-collateral synapses in vitro.  Consequently, the injection of histone deacetylase 
inhibitors prior to contextual fear conditioning enhanced formation of long-term memory 
in vivo (Levenson et al. 2004).  However, there is evidence suggesting that nonspecific 
HDAC inhibitors, including sodium valproate, sodium butyrate and vorinostat, only 
blocked the activity of class I HDACs (Kilgore et al., 2010).  The inhibition of class I 
HDACs using these nonspecific inhibitors restored contextual memory in an early stage 
Alzheimer’s disease APPswe/PS1dE9 double-transgenic mouse model (Kilgore et al., 
2010).  This indicates that some HDACs are more crucial in the regulation of long-term 
memory than others.  Indeed, Guan et al. revealed that forebrain overexpression of 
HDAC2, but not HDAC1, negatively regulates memory formation, and McQuown et al. 
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illustrated that HDAC3 is also a critical negative regulator of long-term memory (Guan et 
al., 2009; McQuown et al., 2011). 
Fischer et al. (2007) engineered a bi-transgenic mouse model with learning and 
memory deficit by inducing post-natal expression of protein p25. Protein p25 is an 
abnormal truncated form of protein p35 which interacts with a protein kinase Cdk5 to 
regulate normal development of the mammalian central nervous system (Patrick et al., 
2001).  However, the interaction of p25 with Cdk5 can cause neuronal cell death and lead 
to learning and memory deficits (Patrick et al., 1999; Lee et al., 2000; Nath et al., 2000). 
In addition to inhibitors of histone deacetylases, Fischer et al. found that two other 
variables, an enriched environment with a variety of frequently changed toys as well as 
exercise (two wheels for voluntary running) have the ability to increase histone 
acetylation in brain neurons of mice (Fischer, Sananbenesi, Wang, Dobbin, Tsai, 2007; 
Korzus, 2010).  Together, these factors have the ability to reverse learning deficit in bi-
transgenic mice, and re-establish access to long-term memory. 
The chromatin remodeling histone acetyltrasnferase activity of CREBBP (cAMP-
responsive element binding protein binding protein) has also been linked to formation of 
long-term memory and mental deficits (Korzus, 2010; Wood et al., 2005; Alarcon et al., 
2004; Giralt et al., 2011).  Korzus et al. (2010) generated transgenic mice with eliminated 
HAT function of CBP (cAMP-responsive element binding protein).  The results indicated 
the consolidation of short-term memory to long-term memory in these mice was 
impaired, and suppression of transgene expression or administration of HDAC inhibitor 
Trichostatin A restored the long-term memory formation (Korzus et al., 2004).  Similarly, 
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several other studies demonstrated CBP is involved in, and plays a critical role in long-
term memory formation (Wood et al., 2005; Vecsey et al., 2007; Barrett et al., 2011). 
A Rubinstein-Taybi (R-T) syndrome mouse model with less than normal expression 
of CBP was used by Alarcon et al. to examine the effect of histone deacetyltransferase 
inhibitors on mental retardation.  These researchers found that inhibitors of histone 
deacetyltransferase could reverse the mental retardation typical for mice with R-T 
syndrome, offering evidence that this syndrome may result from the abnormal epigenetic 
histone acetylation function of CBP (Alarcon et al., 2004).  Similarly, Giralt et al. (2011) 
demonstrated reduced hippocampal expression of CBP and lower level of histone H3 
acetylation for heterozygous Huntington’s disease knock-in mutant mice (Hdh Q7/Q111) 
compared to wild type mice.  Administration of histone deacetylase inhibitor Trichostatin 
A helped to rescue memory deficits in these Hdh Q7/Q111 mice.  These studies are 
significant because they implicated the promising role of epigenetic regulation in the 
treatment of innate mental diseases. 
It is important to note that DNA methylation and histone acetylation may work in 
concert to regulate long-term memory formation and synaptic plasticity.  Miller et al. 
(2008) found that DNA methyltransferase inhibition blocks memory and memory-
associated acetylation, while increasing histone acetylation before administering DNA 
methyltransferase inhibitor can prevent memory deficits.  A methyl-CpG-binding protein, 
MeCP2, has been reported to function as the medium that connects DNA methylation and 
histone acetylation (Martinowich et al., 2003; Nan et al., 1998; Kokura et al., 2001).  
MeCP2 encodes a 486-amino-acid protein with three recognizable domains: the methyl-
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CpG-binding domain (MBD) that mediates methyl-CpG-binding, a C-terminal domain, 
and the transcriptional repression domain (TRD) that recruits corepressor complexes 
Sin3A, c-Ski and N-CoR (Chahrour & Zoghbi, 2007).  These complexes contain HDAC 
components that function in chromatin remodeling (Shahbazian et al., 2002).  Mutations 
in MeCP2 cause Rett syndrome, a postnatal progressive neurodevelopmental disorder 
characterized by reversal of speech, gradual loss of motor skills and mental impairments 
(Chahrour & Zoghbi, 2007).  Evidence suggests that mutations in MeCP2 lead to 
abnormal histone acetylation; both may play a role in Rett syndrome (Shahbazian et al., 
2002). 
For cancer patients suffering from cognitive decline especially memory loss induced 
by chemotherapy, these above pioneering studies suggest the possibility that epigenetic 
modifications can modify certain gene expression of brain neurons to protect or retrieve 
the ability to remember (Levine, 2008).  Increased knowledge of the interaction between 
epigenetics and neuronal functions could identify intervention(s) that could modify 
epigenetics to alleviate or diminish memory loss associated with chemotherapy. 
 
1.2.3 Anti-cancer and Neuro-protective Effects of Berries 
There is evidence suggesting edible small and soft-fleshed berry fruits may have 
beneficial effects against several types of human cancers.  Berry phytochemicals may 
also potentially sensitize tumor cells to chemotherapeutic agents by inhibiting pathways 
that lead to treatment resistance.  In addition, berry fruit consumption may provide 
protection from therapy-associated toxicities (Seeram, 2008).  That is, berries can inhibit 
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the growth of cancer cells and at the same time protect other normal cells including 
neurons.  From this point of view, berries have the potential to be the perfect natural 
solution to chemotherapy induced cognitive decline. 
Anti-cancer effects of berries are well established.  Some of the known constituents 
in berries that exhibit cancer-preventive effects include vitamins A, C, E and folate acid; 
minerals calcium, selenium and zinc; especially phenolic molecules such as 
anthocyanins, flavonols, flavanols, proanthocyanidins, ellagitannins, and phenolic acids 
(Seeram, 2008).  Six popularly consumed berries (blackberry, black raspberry, blueberry, 
cranberry, RR and strawberry) were evaluated for their phenolic constituents’ ability to 
inhibit the growth of human cancer cell lines.  These included oral (KB, CAL-27), breast 
(MCF-7), colon (HT-29, HCT116), and prostate (LNCaP) tumor cell lines at berry 
concentrations ranging from 25 to 200 µg/mL (Seeram et al., 2006).  The inhibition of 
cell proliferation in all the cell lines was dependent on the concentration of berry extracts. 
Black raspberry and strawberry extracts also showed the most significant pro-apoptotic 
effects against colon cancer cell line HT-29 (Seeram et al., 2006). 
Kresty et al. (2001) evaluated the inhibitory effects of lyophilized black raspberries 
against N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in the 
F344 rats (known for good reproductive performance, big litters, and low levels of 
aggression toward handlers) in the carcinogenesis initiation phase and post initiation 
phase (Holmes, 2003).  They found that feeding rats with lyophilized black raspberries 
significantly reduced tumor incidence, multiplicity, proliferation and preneoplastic lesion 
formation.  Different dosages showed significance at different phases of tumorigenesis.  
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Strawberries were also shown to be effective in the inhibition of NMBA induced 
tumorigenesis in the rat esophagus (Carlton et al., 2001).  However, blueberries were 
shown to have no protective effect against chemical carcinogen (Aziz et al., 2002).  One 
possible explanation could be blueberries do not contain as much ellagic acid, a member 
of ellagitannins most abundant in raspberries and able to reduce DNA damage by 
alkylation (Mandal & Stoner, 1990; Duthie, 2007). 
Although ellagic acid has been shown to be an important factor in the inhibition of 
carcinogenesis, it is clear that other compounds also contribute to this observed inhibitory 
effect.  Xue et al. (2001) examined the anti-malignant transformation activity of several 
extracts from freeze-dried strawberries and black raspberries.  They found that both 
ellagic acid and methanol extracts from both types of berries caused decreased malignant 
transformation in a dose-dependent manner.  The mechanisms for the inhibition of cell 
transformation involve the interaction of berry extracts with DNA binding and repair.  
Since methanol extracts do not contain detectable amounts of ellagic acid, there must be 
other chemicals producing the geno-protective effect (2001). 
Based on these positive results for black raspberries, researchers have extensively 
used them in research to illustrate their benefits against chemically induced esophageal 
and colon cancer (Chen et al., 2006a; Chen, Rose, Hwang, Nines, & Stoner, 2006b; Reen, 
Nines, & Stoner, 2006).  To elucidate the molecular mechanisms involved in 
chemoprevention by black raspberries, Lu et al. (2006) employed the mouse epidermal 
CL 41 cell line to look at the targeted genes and involved transcription factors. They 
postulated that the inhibition takes effect by mediating the signaling transduction 
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pathways leading to activation of proteins AP-1 and NFkB, subsequently resulting in 
down-regulation of VEGF and COX-2 expression.  Contrary to some of the previous 
explanations (Stoner et al., 1990; Duthie, 2007), Lu’s group showed methanol-extracted 
fraction to be the major fraction responsible for the inhibitory activity of black 
raspberries (Lu, Li, Zhang, Stoner, & Huang, 2006).  This contradiction again illustrates 
the unclear understanding of berry constituents, which is an important reason for the use 
of whole natural berries instead of the extracts of constituents. 
Although there is clear evidence that berries can act against carcinogenesis in vitro 
and in vivo using animal models, the confirmation in humans has not been well 
established.  A pilot study done by Kresty et al. (2006) examined the chemo-preventive 
effects of black raspberries on patients with Barrett’s esophagus, a premalignant 
esophageal condition that significantly increases the risk of patients to develop 
esophageal adenocarcinoma.  The preliminary results of 10 patients in Kresty’s study 
showed daily consumption of lyophilized black raspberries promotes reduction of two 
markers of oxidative stress in the urinary excretion of the patients (Kresty et al., 2006). 
Polyphenols widely present in berries have been reported to have neuro-protective 
effects (Shin, Park, & Kim, 2006; Kang et al., 2006; Ramiro-Puig et al., 2009; Joseph et 
al., 2009; Fortalezas et al., 2010; Pannangrong, Wattanathorn, Muchimapura, Tiamkao, & 
Tong-un, 2011).  For example, Bastianetto et al. (2009) have shown that in vitro, 
resveratrol protects hippocampal cells against β-amyloid induced toxicity, a key factor in 
the pathway of developing Alzheimer’s disease (AD).  
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Shin et al. (2006) looked at the protective effects of anthocyanins against focal 
cerebral ischemic injury in rats. The pre-treatment of anthocyanins significantly reduced 
the brain infarct volume and TUNEL positive cells that were induced by middle cerebral 
artery occlusion and reperfusion. They also suggested that anthocyanins reduced neuronal 
damage caused by focal cerebral ischemia by blocking the JNK and p53-signalling 
pathway.  Kang et al. (2006) investigated the neuro-protective effects of cyanidin-3-O-β-
D-glucopyranoside (C3G), an aglycon of anthocyanin from the mulberry fruits on 
neuronal cell damage. They found that the C3G extract inhibited the cerebral ischemic 
damage caused by oxygen glucose deprivation in vivo. 
Of particular interest to this dissertation research are the anti-cancer and neuro-
protective effects of RR (Rubus idaeus).  Research from this lab indicates unfractionated 
aqueous RR extract can significantly inhibit mutagenesis by direct-acting and 
metabolically activated carcinogens, and inhibit cancer cell proliferation.  This effect is 
not all due to the antioxidant activity of RR, but the combination of all the characteristics 
of berry extracts (Wedge et al., 2001; Smith et al., 2004; Tate et al., 2003; Tate et al., 
2004; Seeram et al., 2006; God et al., 2010).  This dissertation study in our lab is the first 
research that specifically looks at neuro-protective effects of unfractionated aqueous RR 
in chemotherapy-treated neurons. 
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CHAPTER TWO   MATERIALS AND METHODS 
This chapter provides a description of materials, experimental designs, experimental 
procedures, measurements, and statistics used in this dissertation study.  
The rat PC12 pheochromocytoma cell line (CRL-1721) obtained from American 
Type Culture Collection (ATCC) (Manassas, VA) was used as a cell model in this study.  
This cell line exhibits neuronal behavior when grown in the presence of NGF and is 
considered a standard cell model for neuronal study (Adler, Gough, & Blundon, 2006).  
Cells were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium from 
ATCC supplemented with 5% heat-inactivated horse serum from Atlanta Biologicals 
(Atlanta, GA), 10% fetal calf serum from Atlanta Biologicals and 1% 
penicillin/streptomycin from Sigma Aldrich (St. Louis, MO) at 37 °C, in a 5% CO2 
humidified incubator till treated (2006).   
Doxorubicin hydrochloride was obtained from Sigma Aldrich.  As instructed by the 
manufacturer, the drug was dissolved in Dimethyl Sulfoxide (DMSO) to 100 µM and 
refrigerated at 4°C until used to treat PC12 neuronal cells (Sigma Aldrich, 2012). 
Freeze-dried RR were obtained from the Meeker Variety at Van Drunen Farms 
(Momence, IL).  Five grams of berries were placed into 35mL of distilled water and then 
centrifuged 10 minutes at 3000rpm.  The supernatant was removed and centrifuged for an 
additional 10 minutes at 3000rpm.  This process was repeated, and the final supernatant 
sterilized through a 0.20-µm-pore-size filter from Nalgene Labware (Rochester, NY).  
The sterilized RR extract was then digested and refrigerated at 4°C until used to treat 
PC12 neuronal cells (See Appendix B for Digestion Protocol).  
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2.1 Effects of Doxorubicin on Metabolic Activity of PC12 Neuronal Cells 
The objective of this experiment was to evaluate the effects of DOX chemotherapy 
on metabolic activity of NGF induced PC12 neuronal cells.  As shown in Figure 2.1, 48 
hours prior to treatments, PC12 cells were plated in 96-well plates coated with collagen 
from Sigma (See Appendix B for Collagen Coating Protocol) at a density of 1×105 
cells/well (Adler et al., 2006).  Plated cells were maintained in 1:5 diluted serum with 100 
ng/mL of NGF from Sigma in RPMI (Adler et al., 2006). Treatments were a 48-hour 
incubation of NGF induced PC12 neuronal cells in 1:5 diluted medium and serum with 
various doses of DOX (0.001µM, 0.01µM, 0.1µM, 1µM, 10µM). 
Metabolic activity of PC12 neuronal cells was assessed using the CellTiter 
96®Aqueous Non-Radioactive Cell Proliferation Assay from Promega (Madison, WI).  
This colorimetric assay converts (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS), a tetrazolium 
compound, into formazan that is soluble in tissue culture medium by dehydrogenase 
enzymes found in metabolically active cells.  Formazan absorbance at 490 nm is directly 
proportional to the number of metabolically active cells in the sample.  After treating the 
plate with working solution, MTS and RPMI plus serum with a ratio of 1:5, it was 
incubated for 2-4 hours at 37 °C, in a 5% CO2 humidified incubator.  Absorbance at 
490nm was measured using the Tecan Infinite m200 microplate reader (Durham, NC). 
MTS data was analyzed using standard statistical program in Microsoft Excel.  In  
each experiment, culture plates were done in octuplets.  For each condition, the counts 
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were averaged.  Because the number of control colonies varied slightly from one 
experiment to another, the data for each experiment were normalized to the average of 
controls for that experiment.  Three independent plates for each set of experiment were 
completed on different days.  The nomalized data were then averaged from the three 
independent plates.  The MTS data were compared by two-tail Student t-test, with p 
<0.05 considered statistically significant.  Unless otherwise described, all MTS data was 
analyzed using this methodology. 
 
2.2 Effects of in Vitro Digested Red Raspberry on Metabolic Activity of PC12 
Neuronal Cells 
The objective of this experiment was to evaluate the effects of in vitro digested RR 
on metabolic activity of NGF induced PC12 neuronal cells.  As shown in Figure 2.2, 48 
hours prior to treatments, cells were plated in 96-well plates coated with collagen at a 
density of 1×105 cells/well.  Plated cells were maintained in 1:5 diluted medium and 
serum with 100 ng/mL of NGF.  Treatments were a 48-hour incubation in 1:5 diluted 
medium and serum with various percentages of digested RR (0.0625%, 0.125%, 0.25%, 
0.5%, and 1%).  The metabolic activity was assessed as described in Section 2.1.  
 
2.3 Effects of in Vitro Digested Red Raspberry on Metabolic Activity of 
Doxorubicin Treated PC12 Neuronal Cells 
The objective of this experiment was to look at the effects of in vitro digested RR on 
metabolic activity of DOX treated PC12 neuronal cells.  As shown in Figure 2.3, 48 
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hours prior to treatments, the cells were plated in 96-well plates coated with collagen at a 
density of 1×105 cells/well.  Plated cells were maintained in 1:5 diluted medium and 
serum with 100 ng/mL of NGF.  Two different concentrations of DOX, one percentage of 
digested RR, and the combination of them were added to growth medium of NGF 
induced PC12 neuronal cells.  Specifically, cells were treated with DMSO, 0.1% digested 
RR, 1µM of DOX, 0.1µM of DOX, the combination of 0.1% digested RR and 1µM of 
DOX, and the combination of 0.1% digested RR and 0.1µM of DOX.  Forty-eight hours 
after treatment, metabolic activity was measured as described in Section 2.1. 
 
2.4 Effects of in Vitro Digested Red Raspberry on Neurite Growth of 
Doxorubicin Treated PC12 Neuronal Cells 
The objective of this experiment was to look at the effects of in vitro digested RR on 
neurite growth of DOX treated PC12 neuronal cells.   
As shown in Figure 2.4, 48 hours prior to treatments, cells were plated in 96-well 
plates coated with collagen at a density of 1×104 cells/well.  Plated cells were maintained 
in 1:5 diluted medium and serum with 100 ng/mL of NGF.  Two different concentrations 
of DOX, one concentration of digested RR, and the combination were added to growth 
medium of NGF induced PC12 neuronal cells.  Specifically, cells were treated with 
DMSO, 0.1% digested RR, 1µM of DOX, 0.1µM of DOX, the combination of 0.1% 
digested RR and 1µM of DOX, and the combination of 0.1% digested RR and 0.1µM 
Molar of DOX.  Pictures of neurite growth of PC12 neuronal cells were taken using 
Canon Powershot S5 IS digital camera on a MEIJI TECHNO TC5300 microscopy with 
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CAMEROWINDOW software at a magnification of 800.  Each picture depicted the spot 
with the greatest number of neurites for each sample. 
 
2.5 Effects of Human Plasma Collected Prior to and After Red Raspberry 
Consumption on Doxorubicin Treated PC12 Neuronal Cells 
The objective of this experiment was to look at the effects of human plasma prior to 
and after RR consumption on DOX treated PC12 neuronal cells.  Human blood plasma 
from a previous IRB approved study was used to treat NGF induced PC12 neuronal cells 
(See Appendix C for IRB approval).  In a previous study (Romero, 2011), freeze-dried 
RR were given to 16 healthy volunteers whose eligibility was determined by a diet and 
health questionnaire.  Participants were asked to refrain from eating fruits, fruit-related 
foods or juices for two days.  Blood was drawn prior to the consumption of freeze-dried 
RR, and 2-4 hours after consumption of 2 cups/day of RR with their regular diet for 3.5 
days.  Plasma was seperated from the blood and stored in -20 °C freezer until used to 
treat PC12 neuronal cells.  Plasma from 6 of 18 participants were selected to treat cells 
since questionnaires showed it to be free of known interfering factors such as curry 
intake, supplement intake and menses. 
As shown in Figure 2.5, 48 hours prior to treatments, PC12 cells were plated in 96-
well plates coated with collagen at a density of 1×105 cells/well.  Plated cells were 
maintained in RPMI and 15% autologous human plasma with 100 ng/mL of NGF.  
Treatments were a 48-hour incubation in DMSO control, DMSO plus doxorubicin 
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control, and combinations of 15% autologus human plasma ( pre-plasma or post-plasma) 
and 1µM of DOX.  Metabolic activity was measured as described in Section 2.1. 
 
2.6 Effects of Doxorubicin, in Vitro Digested Red Raspberry and Combination 
on DNA Methylation of PC12 Neuronal Cells 
The objective of this experiment was to compare the effects of DOX, in vitro 
digested RR and their combinations on DNA methylation of NGF induced PC12 neuronal 
cells.  As shown in Figure 2.6, 72 hours prior to treatments, the PC12 cells were added to 
culture flasks coated with collagen at a density of 5×105 cells/plate.  Plated PC12 cells 
were maintained in 1:5 diluted medium and serum with 100 ng/mL of NGF.  One 
concentration of DOX, one percentage of digested RR, and the combination of them were 
added to growth medium of NGF induced PC12 neuronal cells.  Specifically, NGF 
induced PC12 neuronal cells were treated with DMSO, 0.1% digested RR, 1µM of DOX, 
and the combination of 0.1% digested RR and 1µM of DOX.  Seventy-two hours after 
treatments, the PC12 neuronal cells were harvested, suspended in phosphate buffered 
saline (PBS) and stored in -20°C freezer until DNA isolation. 
DNA isolation was performed using the QIAamp DNA mini kit from QIAGEN 
(Valencia, CA).  Briefly, lysis buffer was added to treated PC12 neuronal cells.  The 
mixture was then transferred to a pin column to bind DNA.  After washing several times 
with wash buffer, purified DNA was eluted and harvested into a micro-centrifuge tube.  
The concentration of DNA in each sample was measured using NanoDrop 2000 
spectrophotometer from Thermo Scientific (Pittsburgh, PA).  All samples were adjusted 
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to the same final DNA concentration by adding Polymerase Chain Reaction (PCR) water 
from Promega (Madison, WI). 
Bisulfite treatment was performed using EpiTect Bisulfite Kit from QIAGEN 
(Valencia, CA).  Approximately 1 µg of DNA sample was diluted with dilution buffer 
and incubated for 6 hours in freshly prepared CT Conversion Reagent.  Only 
unmethylated cytosine should be converted to uracil.  Methylated cytosine should remain 
unchanged. After treatment, the mixture was passed through a pin column to bind DNA 
and washed several times with wash buffer.  Finally, bisulfite treated DNA was recovered 
by adding elution buffer and stored in -20 °C until use.  The sample concentration of 
bisulfite treated DNA was measured using NanoDrop 2000 spectrophotometer.  Bisulfite 
treated DNA samples were adjusted to the same final concentration with PCR water. 
A pair of primer sets was designed to amplify either methylated or unmethylated 
DNA based on the difference between their sequences after bisulfite treatment.  Primers 
are designed using the online tool, Meth Primer (Li & Dahiya, 2002), and ordered from 
eurofins (Mebane, NC).  Highly methylated rat genomic DNA from Epigendx 
(Worcester, MA) was used to test the validity of primers for methylated DNA.  As shown 
in Table 2.1, methylated-specific primers and unmethylated-specific primers for BDNF, 
CREB, EGR1, FOS, Nr3C1, TNF, and Tp53 genes were designed.  Among these, primers 
for BDNF, EGR1, and FOS genes were verified to work in PCR (listed bold in Table 
2.1), while the other primers for CREB, TNF, Nr3C1 and Tp53 did not yield products in 
PCR. 
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The PCR mixture, which was made up to 20µL with PCR water, contained bisulfite-
treated DNA (2µM), forward primer (2.5µM), reverse primer (2.5µM), Taq master mix 
from Promega (10µM).  Reaction was performed in a thermo cycler with the settings of 1 
cycle at 95°C for 10 min, 40 cycles at 95°C for 15 sec, 59°C for 30 sec, and 10°C till use.  
Three repeats for samples from different days were performed for each primer set.  The 
concentration of PCR products in each sample was measured using NanoDrop 2000 
spectrophotometer.  All DNA samples were then adjusted to the same final concentration.  
PCR products were analyzed by electrophoresis through a Mini ReadyAgarose 
Electrophoresis Gel 161-3006 from Bio -Rad (Hercules, CA) with TBE and 3% agarose 
plus ethidium bromide to determine the methylation status of the DNA. 
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CHAPTER THREE   RESULTS 
 
This chapter describes results corresponding to each experiment described in 
Chapter Two.  All MTS data were compared by two-tail Student t-test as described in 
Section 2.1, with p < 0.05 considered statistically significant. 
 
3.1 Effects of Doxorubicin on Metabolic Activity of PC12 Neuronal Cells 
The cells were cultured in plates for 48 hours in the presence of various amounts of 
DOX and their metabolic activity were measured as described in Section 2.1.  Since DOX 
was dissolved in DMSO, a DMSO control was also included.  As shown in Table 3.1 & 
Figure 3.1, the metabolic activities of PC12 neuronal cells treated with various 
concentrations of DOX were all statistically different from the DMSO control (p < 0.05).  
Compared to control, as low as 0.001µM of DOX reduced the metabolic activity of PC12 
neuronal cells by over 10% with statistical significance (p = 0.032).  With the increase of 
the concentration of DOX from 0.001µM to 1µM, the metabolic activity decreased 
gradually.  Metabolic activity decreased abruptly when the concentration of DOX is 
greater than 1µM (p = 0.017). 
 
3.2 Effects of Digested Red Raspberry on Metabolic Activity of PC12 Neuronal 
Cells 
PC12 neuronal cells were cultured in plates for 48 hours in the presence of various 
amounts of in vitro digested RR and their metabolic activity were measured as described 
 36 
in Section 2.2.  Since digested RR was dissolved in water, a water control was also 
included.  As shown in Table 3.2 & Figure 3.2, there was a trend of increased metabolic 
activity for 0.0625% to 0.5% digested RR treated PC12 neuronal cells and decreased 
metabolic activity for 1% of in vitro digested RR treated PC12 neuronal cells compared 
to control. 
 
3.3 Effects of in Vitro Digested Red Raspberry on Metabolic Activity of 
Doxorubicin Treated PC12 Neuronal Cells 
PC12 neuronal cells were treated with 0.1% in vitro digested RR, 0.1µM and 1µM 
of DOX, and their combinations as described in Section 2.3.  As shown in Table 3.3 & 
Figure 3.3, the mean metabolic activity of PC12 neuronal cells treated with combinations 
of in vitro digested RR and DOX (1.178 & 1.088) were higher compared to that of cells 
treated with DOX alone (0.966 & 0.897) (p = 0.035 & 0.057 respectively).  With 
increased concentration of DOX from 0.1µM to 1µM, the mean differences between 
metabolic activities of PC12 neuronal cells treated with and without in vitro digested RR 
decreased from 0.212 to 0.191. 
 
3.4 Effects of in Vitro Digested Red Raspberry on Neurite Growth of 
Doxorubicin Treated PC12 Neuronal Cells 
PC12 neuronal cells were treated with 0.1% in vitro digested RR, 0.1µM and 1µM 
of DOX, and their combinations as described in Section 2.4.  The representative neurite 
growth of NGF induced PC12 neuronal cells is illustrated in Figure 3.4.  The labels of the 
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pictures A-F correspond to A-F in Figure 3.3.  Cells treated with in vitro digested RR had 
more neurite connections compared to control cells treated with DMSO.  It appears that 
cells treated with digested RR plus DOX had increased neurite connections compared to 
cells treated with DOX alone, but a more extensive set of experiments must be done to 
confirm this. 
 
3.5 Effects of Human Plasma collected prior to and After Red Raspberry 
Consumption on Doxorubicin Treated PC12 Neuronal Cells 
The effect of in vivo human metabolized RR as a neuroprotectant against neurotoxicity of 
DOX was evaluated by comparing PC12 neuronal cells treated with human plasma collected 
prior to freeze-dried RR consumption (pre-plasma) to cells treated with human plasma collected 
after freeze-dried RR consumption (post-plasma).  PC12 neuronal cells were treated with 1µM of 
DOX, 15% pre-plasma, 15% post-plasma, and DOX plus plasma as described in Section 2.5 .  
The metabolic activity ratio for PC12 neuronal cells treated with plasma plus DOX to PC12 
neuronal cells treated with plasma alone was calculated for both pre-plasma and post-plasma.  As 
shown in Figure 3.5, the ratio for pre-plasma and post-plasma was compared for each participant.  
A higher ratio for post-plasma compared to pre-plasma can indicate the effectiveness of in vivo 
metabolized RR as a neuroprotectant against DOX chemotherapy. 
The calculated ratios for post-plasma of participants #1-#4 were higher compared to ratios 
of their pre-plasma, while the calculated ratios for post-plasma of participants #5-#6 were lower 
compared to ratios of their pre-plasma.  The average ratio of post-plasma for six participants was 
higher than that of pre-plasma with no statistical significance.  The differences between post-
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plasma ratio and pre-plasma ratio calculated by dividing post-plasma ratio by pre-plasma ratio 
for each donor (#1-#6) are: 1.34, 1.19, 1.12, 1.05, 0.79, 0.84. 
 
3.6 Effects of Doxorubicin, in Vitro Digested Red Raspberry and Combination 
on DNA Methylation of PC12 Neuronal Cells 
Methylation specific PCR (MSP) primers for EGR1, NR3C1/GR, BDNF, TNF, 
Tp53, CREB, and FOS genes were designed.  Methylated-specific primers for BDNF, 
EGR1, and FOS were verified to work in MSP using highly methylated rat genomic 
DNA.  Highly methylated rat genomic DNA is in vitro enzymatically methylated 
genomic DNA that serves as positive control in DNA methylation analysis.  As shown in 
Figure 3.6, among the seven screened genes, BDNF, EGR1, and FOS showed 
methylation bands on electrophoresis gels for highly methylated rat genomic DNA, 
indicating these designed methylated-specific primers can be used in MSP.  In Figure 3.7, 
BDNF, EGR1, and FOS showed unmethylated bands for DNA of PC12 neuronal cells, 
indicating these designed unmethylated-specific primers can be used in MSP. 
Verified methylated-specific and unmethylated-specific primers were used to screen 
methylation pattern of DNA from the control and treated PC12 neuronal cells by MSP.  
As shown in Table 3.4, the methylation pattern of EGR1 and BDNF is the same for DNA 
of control, DOX treated, digested RR treated, and combination treated PC12 neuronal 
cells; methylation pattern of FOS changed for DNA of DOX and combination treated 
PC12 neuronal cells compared to control and in vitro digested RR treated cells. 
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As shown in Figure 3.8, FOS showed unmethylated bands on electrophoresis gel for 
DNA from PC12 neuronal cells, indicating the designed unmethylated-specific primers 
worked in MSP; FOS showed methylated bands on electrophoresis gel for highly 
methylated rat genomic DNA, indicating the designed methylated-specific primers 
worked in MSP.  As shown in Figure 3.9, using verified FOS methylated-specific primers 
and unmethylated-specific primers in MSP for DNA from the control and treated PC12 
neuronal cells harvested from three different days, DNA of DOX treated and combination 
treated PC12 neuronal cells showed a different methylation pattern compared to DNA of 
control and digested RR treated PC12 neuronal cells.  Specifically, all the DNA from 
control and treated PC12 neuronal cells has unmethylated FOS gene, and only DNA of 
DOX treated and combination treated PC12 neuronal cells has methylated FOS gene.  As 
shown in Table 3.5, screening of methylation pattern of FOS gene for DNA from the 
control and treated PC12 neuronal cells harvested from seven different days indicates that 
not all the PC12 neuronal sample sets have methylated FOS gene for DOX treated and 
combination treated cells.  However, as shown in Figure 3.10, a majority of the screened 
sample sets showed a difference in the methylation pattern of FOS for DNA from DOX 
treated and combination treated PC12 neuronal cells compared to the control and in vitro 
digested RR treated cells. 
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CHAPTER FOUR   DISCUSSION 
This chapter focuses on interpretation of results of this dissertation research in light 
of other published results.  Special attention will be on dosage and mechanisms for 
neuronal toxicity of DOX, possible mechanisms for the protective effects of red raspberry 
from neurotoxicity induced by DOX, variability of protective effects of RR in vivo, and 
DNA methylation changes associated with DOX treatment in PC12 neuronal cells. 
 
4.1 Dosage and Mechanisms for Neuronal Toxicity of Doxorubicin 
This study showed as little as 0.001µM of DOX reduced the metabolic activity of 
PC12 neuronal cells by over 10% (p < 0.05 by student t-test) (Figure 3.1).  Dietrich and 
colleagues also showed in vitro and in vivo that lower dosages of chemotherapy agents 
were needed to cause neuronal cell death compared to dosages needed for tumour cell 
death (Dietrich, Han, Yang, Mayer-Proschel, & Nobel, 2006).  These results are clinically 
significant because historically most of the chemotherapy drugs are not believed to be 
capable of crossing the blood-brain barrier, but revealing research indicates the genetic 
variability in drug transporters in the blood-brain barrier and pharmocogenetic factors 
may allow minute leakage of toxic chemotherapy into delicate brain neurons (Ahles & 
Saykin, 2007).  This minute amount of leak might be enough to cause abnormalities of 
brain neurons, yielding a reduction in metabolic activity of brain neuronal cells.   
In addition, this present study indicates greater than 1µM of DOX treatment is 
associated with an abrupt decrease in PC12 neuronal cell metabolic activity (Figure 3.1).  
With increased concentration of DOX from 0.1µM to 1µM, the differences between 
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metabolic activity of PC12 neuronal cells treated with and without digested RR decreased 
(Figure 3.3).  This indicates at higher concentrations of DOX, the mechanism for the 
decrease of PC12 neuronal cell metabolic activity may have shifted.  Lopes and 
colleagues found similar results specifying for concentrations up to around 0.5µM, cell 
death follows an apoptotic pattern, while for higher concentrations, apoptosis is inhibited 
and necrosis becomes dominant (Lopes et al., 2008).  Another study indicates that DOX 
has the capacity to cause apoptotic neuronal cell death by disturbing mitochondrial 
respiration.  It reports that DOX administration can increase levels of pro-apoptotic 
proteins Bax and p53 in brain mitochondria of mice.  As shown in Figure 4.1, protein 
Bax forms complex with p53 leading to cytochrome c release to activate caspase 3 and 
initiate programmed neuronal cell death (Tangpong et al., 2006).  The present study 
suggests that RR may only protect the PC12 neuronal cells from apoptosis caused by 
minute amount of DOX, not necrosis caused by higher amount of DOX. 
Other mechanisms responsible for the toxic effects of DOX on neuronal functions 
are proposed to be drug-induced free radical mediated oxidative stress, metabolized 
products that can pass the blood-brain barrier, and DNA damage.  First, DOX can 
increase protein oxidation, protein nitration, lipid peroxidation, and DNA/RNA oxidation 
by generating super-oxide radical O2- (Butterfield & Kanski, 2001; Cardoso et al., 2008; 
Joshi et al., 2005; Joshi et al., 2007; Muller, Jenner, Bruchelt, Niethammer, & Halliwell, 
1997; Tangpong et al., 2007).  As shown in Figure 4.2, super-oxide radical O2- 
participates in redox cycling activated by nitric oxide synthase and cytochrome P450, and 
reacts with H2O2 and other reactive species to produce reactive oxygen species (ROS) 
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and reactive nitrogen species (RNS), leading to oxidative damages with neuronal 
dysfunction and neuronal cell death (Halliwell & Gutteridge, 1999; Gutierrez, 2000; 
Deres et al., 2005).  Increased levels of oxidation have been observed in brains of 
different types of mice with mild cognitive decline induced by DOX (Joshi et al., 2005; 
Tangpong et al., 2007; Cardoso et al., 2008).  The brain is thought to be particularly 
vulnerable to oxidative stress because of: 1) large component of polyunsatrurated fatty 
acids; 2) elevated oxygen demand; and 3) relatively low antioxidant capacity (Joshi et al., 
2007; Aluise et al., 2010).  These results could indicate that oxidative stress may be a 
mechanism causing cognitive impairments in cancer patients treated with DOX 
chemotherapy.  
Furthermore, DOX induces cytokine (such as tumor necrosis factor alpha, TNF-α) 
production, which can pass through the blood-brain barrier and stimulate local cytokine 
production, inflammation, and oxidative stress (Tangpong et al., 2006; Aluise et al., 
2010).  In the brain, TNF-α can activate local cytokine production and generates nitric 
oxide synthase (NOS) (Szelenyi, 2001).  NOS is the enzyme important in the generation 
of nitric oxide (NO), one of reactive nitrogen species (RNS) (Tangpong et al., 2007) 
(Figure 4.3).  Nitric oxide is involved in nitration of proteins in mitochondria, such as 
MnSOD, leading to accumulation of O2- and further oxidative stress (Tangpong et al., 
2007). 
Finally, as shown in figure 4.4, DOX can intercalate into DNA, inhibit 
topoisomerase II, preventing replication and cell growth, leading to DNA breaks and cell 
death.  Although DOX interacts with other cellular targets, the interaction with DNA is 
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believed essential for its effects (Frederick et al., 1990).  It has been reported that DOX 
binds DNA sequence CGATCG to inhibit micromolecular biosynthesis (Frederick et al., 
1990; Momparler, Karon, Siegel, & Avila, 1976). Doxorubicin prevents unwinding of 
DNA for replication by interacting with helicases, and leads to DNA breaks by inhibiting 
topoisomerase II religation activity. (Bachur et al., 1992; George, Ghate, Matson, & 
Besterman, 1992; Sander & Hsieh, 1983; Tewey, Rowe, Yang, Halligan, & Liu, 1984). 
Taken together, minute amounts of DOX decreased metabolic activity of PC12 
neuronal cells in vitro.  With higher concentration of DOX, the mechanism for the 
decrease of neuronal cell activity may have shifted from apoptosis to necrosis.  Several 
mechanisms may account for this effect including direct neuronal toxicity, initiation of 
the apoptotic pathway, stimulation of cytokine production and oxidative stress, and 
interaction with DNA.  As shown by the results of this study, the interaction between 
DOX and DNA may be not limited to intercalation and replication interference. 
Epigenetics may play a role to influence specific gene expression and sebsequent 
neuronal cell functions. 
 
4.2 Possible Mechanisms for the Protective Effects of Red Raspberry from 
Neurotoxicity Induced by Doxorubicin  
Red raspberry (Rubux idaeus L.) is an economically important berry crop with high 
levels of antioxidants and complex mixtures of phytochemicals that provide protective 
health benefits through a combination of additive and/or synergistic effects (de Ancos et 
al., 2000; Anttonen & Karjalainen, 2005; Joseph et al., 2009). 
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This present study revealed low percentages of in vitro digested RR alone increased 
the metabolic activity of PC12 neuronal cells without statistical significance (Figure 3.2).  
In vitro digested RR counteracted the neurotoxic effects of low concentrations of DOX 
chemotherapy in PC12 neuronal cells including decreased metabolic activity (Figure 3.3) 
and fewer neurite connections (Figure 3.4).  These data emphasize results from other 
studies showing that berries display neuroprotective effects in various in vitro and in vivo 
models of toxicity (Shin et al., 2006; Kang et al., 2006; Ramiro-Puig et al., 2009; Joseph 
et al., 2009; Fortalezas et al., 2010; Pannangrong et al., 2011).  They also suggest RR 
consumption may be a potential natural intervention to protect against chemotherapy 
induced cognitive decline. 
As shown in Figure 4.5, the mechanisms responsible for the neuroprotective effects 
of RR against DOX chemotherapy likely include the high antioxidant activity, 
involvement in anti-inflammatory/anti-stress signaling pathways, inhibition of apoptotic 
pathways, and genoprotective effect of phenolic compounds in berries (Barros et al., 
2006; Kang et al., 2006; Shin et al., 2006; Joseph et al., 2009; Fortalezas et al., 2010; 
Pangnangrong et al., 2011). 
Phenolics are classified by their structural characteristics into several categories 
including flavonoids (flavanols/catechins, flavonols, flavones, flavanones, isoflavonoids, 
anthocyanins), phenolic acids, stilbenes, tannins, and lignans (Alwerdt et al., 2008; Han 
et al., 2007; Liu et al., 2002; Paredes-López, Cervantes-Ceja, Vigna-Perez, & Hernandez-
Perez, 2010).  These phenolic compounds are known to provide a variety of health 
benefits including antioxidant, anti-allergic, anti-carcinogenic, antimicrobial, anti-
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mutagenic and anti-inflammatory effects (Benavente-Garcia, Castillo, Marin, Ortuno, & 
Rio, 1997; Do, Kang, Kim, Jo, & Lee, 2004; Kim, Heo, Kim, Yang, & Lee, 2005; 
Murakami et al., 2000; Wang, Provan, & Heliwell, 2000; Yoshimura, Nakazawa, & 
Yamaguchi, 2003). 
High amounts of total phenolic compounds especially anthocyanins, ellagic acid, 
flavonols, and stilbenes in RR contribute to their capacity to scavenge free radicals 
(Wang and Lin, 2000; Liu et al., 2002).  As many as 11 anthocyanins have been 
identified in raspberries (de Ancos, Gonzales, & Cano, 1999; Mullen et al., 2002).  
Anthocyanins are hydrophilic pigments that introduce red or purple colors to fruits, 
vegetables and rice (Pannangrong et al., 2011).  The properties of anthocyanins have been 
reported to include the chelation of metal ions, inhibition of lipid oxidation, impact on 
cell cycling, suppression of tumors, modulation of signal transduction and apoptosis, 
detoxifying enzymes and metabolism, and scavenging of free radicals (Chun, Kim, & 
Lee, 2003; Kim et al., 2004; Liu et al., 2002; Han et al., 2007; Wang et al., 1997;).  For 
example, Kang et al. (2006) concluded cyaniding-3-glucoside, a major anthrocyanin, 
helps to protect PC12 neuronal cells from H2O2 induced oxidative damage.  As 
mentioned in Section 4.1, H2O2 reacts with DOX induced O2- leading to oxidative 
damages to neuronal cells. In addition, anthocyanins can be absorbed by brain 
enthothelial cell lines, and potentially cross the blood-brain barrier (Youdim et al., 2003).  
Therefore, anthocyanins may play a role in the neuroprotective effect of RR against DOX 
chemotherapy in vitro, and possibly in vivo. 
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Ellagic acid, another phenolic compound, is commonly found as ellagitannins with 
high concentrations in raspberries (Anttonen & Karjalainen, 2005).  It has been shown to 
have antioxidant activity, anticarcinogenic and vasodilation properties (Mullen et al., 
2002).  Flavonols, such as quercetin and kaempferol, are powerful antioxidants with a 
role in the neuro-protective effects of berries (Knekt et al., 2002; Hubbard et al., 2003).  
Stilbenes such as resveratrol, pterostilbene, and piceatannol all possess anti-aging, and 
anti-oxidant activities (Joseph, Fisher, Cheng, Rimando, & Hale, 2008; Matsuda et al., 
2000; Mizuno, Schrader, & Rimando, 2008; Park, Choo, Yoon, & Kim, 2002; Shakibaei, 
Harikumar, & Aggarwal et al., 2009; Wang, Catana, Yang, Roderick, & Van Breemen, 
2002). 
Though each mentioned individual bioactive compound could be responsible for the 
high antioxidant activity of RR, the interactive effects of all the compounds in RR are 
believed to offer a more powerful effect (Pangnangrong et al., 2011).   
However, in this study, when adding in vitro digested RR alone to PC12 neuronal 
cells, the results showed a toxic effect above 0.5% RR treatment (Figure 3.2).  Perhaps 
the lack of protective effect is due to accumulation of numerous active ingredients in RR.  
After adding certain amount of RR, the increased amounts of other ingredients in addition 
to the active ingredient responsible for the antioxidant activity of RR may bring higher 
magnitude of interaction between various ingredients, leading to a masking effect or even 
toxic effect (Pannangrong et al., 2011).  It is also possible that high levels of RR are toxic 
to cell metabolic pathways. 
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A study done by Fortalezas et al. aimed to look at the antioxidant properties and 
neuro-protective capacity of strawberry tree fruit.  However, when raspberries were used 
as control, it was found that although strawberry tree fruit has similar levels of 
polyphenols as raspberries, and higher amount of antioxidants, the strawberries did not 
show more neuro-protective effects.  On contrary, when used in a neurodegeneration cell 
model, raspberries increased neuroblastoma survival by 36.6%.  The study concluded 
raspberries have promising neuro-protective effects, and this protection is not all due to 
antioxidant activity (Fortalezas et al., 2010).  This conclusion reinforced the theory that 
multiple mechanisms work together additively or synergistically to produce the neuro-
protective effects of raspberries (2010). 
A possible mechanism is the enhancement of neuronal interaction via increases in 
neuronal signaling and decreases in stress signals induced by oxidative/inflammatory 
stressors (E.g. NFκB, TNFα).  Findings from Williams et al. (2008) suggested berries 
can improve the performance of aged rats in memory tasks by activation of CREB and 
increase of BDNF in the hippocampus.  These changes correlate with increased cell 
signaling related kinase, leading to the building up of extra cell signaling.  In addition, 
reports have shown berry supplementation decreased NFκB and TNFα expression in the 
hippocampus of rats fed with kainic acid, an excitotoxin that produces neuronal lesions 
and induces inflammatory response (Goyarzu et al., 2004; Shukitt-Hale et al., 2008).  
Anthocyanins in raspberries have been shown to reduce the level of inflammatory 
mediators in several inflammatory disease models (Rossi et al., 2003; Tsuda, Horio, & 
Osawa, 2002). 
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Anthocyanins in raspberries have been suggested to inhibit apoptotic pathways in 
neurons.  Proteins phospho-c-Jun N-terminal kinase (p-JNK) and p53 are important 
mediators in various signaling pathways involved in apoptotic neuronal cell death 
(Harris, Deshmukh, Tsui-Pierchala, Maroney, & Johnson, 2002; Li, Chopp, Power, & 
Jiang, 1997; Irving and Bamford, 2002; Park et al., 2000; Renolleau, Benjelloun, Ben-
Ari, & Charriaut-Marlangue, 1997; Tournier et al., 2000).  Shin et al. (2006) 
demonstrated that anthocyanin suppressed the activation of JNK and up-regulation of 
p53, and reduced JNK and p53 positive cells in brain. 
Finally, berries have been shown to have geno-protective and behavioral-protective 
effects by Barros et al. who gave a 30-day administration of a lyophilized extract of 
vaccininium ashei berries to Swiss mice to determine the berries’ effects on DNA 
damage in the hippocampus and cerebral cortex as well as cognitive performance. The 
extract reduced DNA damage induced by H2O2 treatments on brain tissue and 
significantly enhanced long-term memory in mice (Barros et al., 2006). 
These discussed mechanisms responsible for neuro-protective effects of berries are 
also the main mechanisms underlying neurotoxicity caused by DOX and cognitive 
decline in cancer patients undergoing chemotherapy.  This reinforced results from this 
dissertation study that RR counteracts neurotoxicity caused by DOX chemotherapy. 
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4.3 Interpersonal Metabolic Differences Account for Variability of Protective 
Effects of Red Raspberry in Vivo 
In vitro research of RR offers preliminary information that RR can counteract the 
neurotoxicity caused by DOX chemotherapy, suggesting a potential for use as an 
intervention for “chemobrain” in clinical practice.  Of concern is the fact that molecules 
reaching human circulation for distribution into tissues are different from the compounds 
originally present in foods (Koli et al., 2010).  Bioactivity and pharmacokinetic properties 
including absorption, distribution, metabolism, and excretion of RR should play a major 
role in its preventive or therapeutic application (Paredes-López et al., 2010).   
Bioactivity level is determined if the concentration of a specific component reaches 
a physiologically significant level at its target sites (Seeram, 2008).  Pharmacokinetic 
properties determine the bioavailability of certain compounds in berries, affected by the 
chemical structures of the compounds and routes of metabolism (Paredes-López et al., 
2010).  The in vitro digested RR used in the in vitro portion of this present study looked 
at the effects of RR on neurotoxicity caused by DOX.  However, this digestion process 
only mimics what is happening in the stomach using pepsin and pancreatic bile salts.  As 
shown in Figure 4.6, metabolism of the compounds in berries not only happens in the 
stomach, but also takes place as the compounds circulate and/or move through the liver, 
colon and small intestines.  Research indicates a majority of berry compounds are 
actually metabolized and absorbed in the liver by cytochrome P450 enzymes and in the 
colon by microflora (Koli et al., 2010; Manach, Scalbert, Morand, Remesy & Jimenez, 
2004).  To better mimic human metabolism, this study used plasma from healthy 
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participants who ingested RR twice a day for over 3.5 days to look at its effects on DOX 
treated PC12 neuronal cells (See Appendix C for IRB approval). 
Moreover, neglecting genetic factors, the blood-brain barrier selectively allows 
certain chemicals in the blood to enter the brain, so metabolized products of drugs or 
foods circulated in blood account for major effect on neronal functions in brain (Dawood 
& Leyland-Jones, 2009).  Human plasma contains most of these metabolized products 
that can be used to treat neuronal cell lines to examine the effects of the metabolized 
products of RR on neuronal functions. Use of plasma from participants who have 
ingested RR for over 3.5 days can mimic the internal environment of the human body 
versus the in vitro digestion of RR.  
In this study, post-plasma from four out of six participants exhibited beneficial 
effects on the metabolic activity of PC12 neuronal cells while the other remaining two had 
negative results.  While the average ratio of post-plasma for six participants was higher 
than that of pre-plasma with no statistical significance, the differences between post-
plasma ratio and pre-plasma ratio calculated by dividing post-plasma ratio by pre-plasma 
ratio for each donor are quite different (#1- #6: 1.34, 1.19, 1.12, 1.05, 0.79, 0.84) 
indicating that the effect could be quite significant for a particular individual, but quite 
different from one individual to another.  It is common to see variability of responses with 
such a small sample size.  Even with large sample sizes, there can be variation in 
outcomes since some people are extensive metabolizers, intermediate metabolizers, poor 
metabolizers or ultrarapid metabolizers, not only for drugs but also natural foods.  This 
variation may be due to large interindividual variations in the plasma concentration of 
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metabolized berries caused by differences in the gastrointestinal metabolic system such as 
microflora, by genetic differences or any other unknown external factors (Mountzouris, 
McCartney, & Gibson, 2007; Rezzi, Ramadan, Fay, & Kochhar, 2007).   
Secondary products with a high level of bioavailabiliy and bioactivity that account 
for the neuroprotective effects of RR are still under research.  Primarily, animal studies 
have been used to study bioavailability of compounds in berries.  For example, 
metabolism and absorption of phenolics are largely dependent on aglycone structure and 
the way it binds to the sugar side chains (Hollman & Katan, 1997; Hollman et al., 1999).  
Those bound to glucose, such as ellagic acid, are absorbed in upper part of the gut, 
stomach or small intestine after hydrolyzation and conjugation; others, such as 
chlorogenic acid, go through the colon where sugar chains are cleaved by enzymes from 
microflora (Olthof, Hollman, Buijsman, van Amelsvoort,  & Katan, 2003; Paredes-López 
et al., 2010).  Anthocyanins are generally considered to be poorly metabolized and 
absorbed in humans and rats (Seeram, 2008).  However, some recent research suggests 
anthocyanins can be absorbed in original forms or unknown modified forms that have 
been biotransformed after ingestion (McGhie & Walton, 2007).  Although phenolics have 
limited levels in the circulation, they may be extensively metabolized or bound to other 
unknown molecules, causing difficulty in lab analysis (Seeram, 2008).  All the 
metabolized and absorbed products of berries may adequately accumulate at target sites 
and work complementarily or synergistically to contribute to the overall effects of RR in 
human body. 
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4.4 Redox Status and FOS Transcription 
Many studies have linked epigenetic mechanisms to neuronal/cognitive function 
postulating that transient reprogramming of epigenetic codes such as DNA methylation 
and histone modifications is required for some basic neuronal/cognitive functions such as 
neurite growth, or memory formation (Feng et al., 2010;Levenson et al., 2006; Miller & 
Sweatt, 2007; Lubin et al., 2008; Korzus, 2010; Korzus et al., 2004; Miller et al., 2008).  
As shown in Figure 1.1, folate acid in RR is a key factor in the epigenetic methylation 
pathway (Abbott, Ronnback, Hansson, 2006; Liu, Wylie, & Tollefsbol, 2003; Niculescu 
& Zeisel, 2002).  The intake of folate acid influences the global  availability of methyl 
groups for DNA or histone methylation.  The methylation of DNA or histone can recruit 
different chromatin remodeling complexes to promote compacting or openning of 
chromatin in order to regulate gene transcription.  The activation and silencing of some 
genes important in brain neuron function can lead to changes in cognitive function 
(Miller & Sweatt, 2007).  Therefore, the original hypothesis of this study was that RR 
treated PC12 neuronal cells had different DNA methylation patterns compared to control 
cells or DOX treated cells.  However, the study revealed different outcomes. 
Table 4.1 shows genes originally planned for screening during the study and the 
functions of their gene products.  Only the methylated- and unmethylated-specific 
primers designed for EGR1, BDNF and FOS genes resulted in products in PCR.  Tested 
primers are listed in Table 2.1. 
Immediate early genes are a set of first genes expressed in response to cellular 
stimulation.  They are usually induced within minutes of stimulation and are transiently 
 53 
expressed (Tischmeyer & Grimm, 1999; O’Donnell, Odrowaz, & Sharrocks, 2012).  
After stimulation, their expression enter an activated phase, then go back to a repressed 
phase and stay at a more than basal level of expression (O’Donnell et al., 2012).  The 
EGR1 gene, also known as Zif 268, Krox-24, NGFI-A, or Zenk, is one of these immediate 
early genes that encode transcriptional factors to interact with the promotor or regulatory 
region of a set of effector genes (Bozon et al., 2002).  It belongs to a multigene family 
encoding closely related transcriptional factors EGR-2 (Krox-20), EGR-3, and EGR-4 
(NGFI-C).  These transcriptional factors are required for cell growth, differentiation and 
apoptosis (Gashler & Sukhatme, 1995; Bozon et al., 2002; Jones et al., 2001).  Among 
these genes, EGR1 has been shown to be necessary for the formation of long-term 
memory (Jones et al., 2001; Bozon et al., 2002). 
This study looked at the methylation pattern of the EGR1 gene in the control, DOX 
treated, RR treated and combination treated PC12 neuronal cells by MSP.  Results 
indicated an unmethylated EGR1 gene for all samples.  That is, there is no difference as 
regard to whether the gene is methylated or unmethylated among the control and the 
treated PC12 neuronal cells.  Unmethylation of genes usually, although not necessarily, 
leads to gene expression and gene products.  High density of methylation usually leads to 
reduction of transcriptional activity (Ebinger, Senf, Wachowski, & Scheurlen, 2004).  
This result can be explained by the finding that the EGR1 gene encodes the protein that is 
expressed responding to NGF treatment in rat PC12 cells (Lemaire, Revelant, Bravo, & 
Charnay, 1988).  Since all the samples were treated by NGF in order to induce 
differentiation of PC12 into neuronal cells, the unmethylated EGR1 gene and its 
 54 
expression is essential for its response to growth factor treatment.  In addition, this result 
also indicates DOX and/or RR treatment(s) did not change DNA methylation pattern of 
EGR1 gene in PC12 neuronal cells. 
BDNF gene is a member of the neurotrophin family, encodes a secreted protein that 
plays an important role in neuronal survival, differentiation, growth and morphology 
maintenance (Aid et al., 2007; Bibel & Barde, 2000; Binder  & Scharfman, 2004; Chao, 
Rajagopal, & Lee, 2006).  It is also implicated essential in memory and learning (Hall, 
Thomas, & Everitt, 2000; Linnarsson, Bjorklund, & Ernfors, 1997; Lubin et al., 2008;)  
The BDNF gene is composed of nine 5’ noncoding exons and one 3’ coding exon.  Each 
of these exons has a promoter region that regulates its transcription.  The combinations of 
different noncoding exons and the common coding exon dictates different mRNA 
isoforms, which are stimulated by cellular stimuli and in turn regulate subsequent 
activities of the transcripts (Aranda-Abreu, Hernandez, Soto, & Manzo, 2005; 
Blichenberg et al., 1999; Lauterborn et al., 1996; Lubin et al., 2008; Nanda & Mack, 
1998; Pal et al., 2003). 
The present study looked at the methylation pattern of BDNF gene of the control, 
DOX treated, RR treated and combination treated PC12 neuronal cells by MSP.  The 
methylated-specific and unmethylated-specific primers were designed to detect the whole 
BDNF gene with nine 5’ noncoding exons and one 3’ coding exon.  There is no 
difference whether the gene is methylated or unmethylated for BDNF among the control 
and groups of treated PC12 neuronal cells.  All the samples showed both strong 
methylation and weak unmethylation signals for BDNF gene (Table 3.4), possibly due to 
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the heterogeneous maturation stages of the NGF induced PC12 neuronal cells. The 
differentiation of PC12 cells into neuron-like cells are characterized by both the extension 
of neurites and the cessation of proliferation (Hahn, Jones, & Meyer, 2009). In this study, 
the differentiation of PC12 cells was determined by visual examination of the neurite 
growth.  Theoretically after six days of induction with NGF, PC12 cells should be 
differentiated into neuron-like cells (Adler et al., 2006).  However, although most of the 
cells developed neurites by the end of treatments, it was not guaranteed that all the cells 
were differentiated.  According to the cell cycle study of PC12 cells, the cells can be 
arrested in both G1 and G2/M phases and neurite growth can take place before cell cycle 
arrest (Hanh, Jones, & Meyer, 2009).  That is, cells that developed neurites may not have 
been arrested and differentiated, thus contributing to the heterogeneity of the cell 
population.?
FOS gene, also belongs to immediate gene family and functions as a transcriptional 
factor to mediate acute extracellular signals/treatments and long-term changes in neuronal 
cells (Chen, Xie, Stevenson, Auron, & Calderwood, 1997; Kovacs, 1998; Hiroi et al., 
1997).  C-Fos, FosB, Fra-1 and Fra-2 are the major protein members of Fos family that 
are encoded by genes containing four exons and three introns (Cohen & Curran, 1988; 
Greenberg & Ziff, 1984; Nishina, Sato, Suzuki, & Iba, 1990; van Straaten, Muller, 
Curran, van Beveren, & Verma, 1983; Zerial et al., 1989).  Fos proteins dimerize with 
members in Jun family including c-Jun, JunB and JunD to form a transcriptional factor 
named activator protein-1 (AP-1) (Kovacs, 1998; Hughes & Dragunow, 1995).  
Heterodimer AP-1 complexes recognize DNA sequence TGACTCA in the regulatory 
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regions of targeted genes to promote or suppress gene expression (Rauscher et al., 1988).  
The regulation of these subsequent genes should be coordinated by several classes of 
regulatory proteins, never a task completed by a single class of proteins (Kovacs, 1998). 
This research looked at the methylation pattern of FOS gene for the control, DOX 
treated, RR treated and combination treated PC12 neuronal cells by MSP.  Results 
indicate DOX treated and combination treated PC12 neuronal cells have a different 
methylation pattern compared to control and RR treated cells.  Specifically, all the 
samples showed unmethylation signals while only DOX treated and combination treated 
PC12 neuronal cells showed methylation signals for FOS gene. 
All the samples in this research showed unmethylation signals for FOS gene, which 
facilitates gene transcription.  This finding reinforced the results of previous studies 
concluding NGF injections or more generally growth factors can induce transcription and 
translation of immediate-early genes including FOS gene (Sharp, Gonzalez, Hisanaga, 
Mobley, & Sagar, 1989; Rivera & Greenberg, 1990).  It was reported that in the case of 
FOS gene, the serum response element, a dyad symmetrical sequence located upstream of 
the gene, responds to the binding of a complex of proteins that are stimulated by growth 
factor signals, in order to activate and repress transcription of FOS (Rivera & Greenberg, 
1990).  However, it is probable this is not the single mechanism that facilitates FOS 
expression.  From the results of the present study, unmethylation of FOS may also play a 
role in the promoting of gene expression in responds to growth factors. 
Only DOX treated and combination treated PC12 neuronal cells showed 
methylation signals for FOS gene in this study.  As discussed in previous sections, DOX 
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treatment leads to oxidative stress in neuronal cells. Activator protein-1, heterodimerized 
by c-Fos and c-Jun proteins, is one of the well characterized redox (reduction-oxidation) 
sensitive transcriptional factors (Kunsch & Medford, 1999; Winyard & Blake, 1997; Sun 
& Oberley, 1996).  Redox sensitive trasncriptional factors are modulated by redox 
sensitive signaling pathways by two levels of mechanisms: 1) transcriptional level and 2) 
post-translational level.  They respond to intracelluar reduction-oxidation status and 
target subsequent genes to regulate the magnitude and specificity of their expressions 
(Kunsch & Medford, 1999).  Theoretically, as the precusor of AP-1 protein, c-Fos 
transcription or translation is possibly regulated first in order to modulate the presence or 
magnitude of AP-1 protein (Sun & Oberley, 1996).  In fact, some researchers have 
reported that c-Fos and c-Jun expression is indeed also regulated by celluar 
environmental redox status (Rao, Lassegue, Griendling, & Alexander, 1993), and the 
activity of AP-1 protein relies on de novo synthesis of c-Fos and c-Jun mRNAs ( Meyer 
et al., 1994).  There is research indicating reductants activate AP-1 activity while 
oxidants inhibit AP-1 activity (Sun & Oberley, 1996).  However, there is also research 
indicating both oxidant H2O2 and antioxidant PDTC induce AP-1 activation, but this 
requires post-translational modification of tyrosine and serine, and mediation of Jun 
protein phosphorylation (Barchowsky, Munro, Morana, Vincenti, & Treadwell, 1995; 
Meyer et al., 1994).  These paradoxical results suggest the complexity of regulation 
networks in the modulation of redox status (Kunsch & Medford, 1999).  DNA 
methylation is one of the mechanisms that regulate transcription of FOS gene, which, 
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from the results of the present study, may also play a role in the response to oxidative 
stress caused by DOX in PC12 neuronal cells. 
In addition, DOX treated cells and DOX plus digested red raspberry treated cells 
both showed the same pattern of unmethylation and methylation signals for FOS gene in 
this study.  This indicates digested red raspberry did not counteract methylation changes 
induced by DOX.  As previously discussed (Section 4.2), the neuro-protective effects 
against DOX exhibited by red raspberry are probably due to the antioxidant, anti-
inflammatory, anti-apoptosis, genoprotective effect of phenolic compounds in berries. 
This research screened sample sets harvested from seven different days.  Each 
sample set includes the control PC12 neuronal cells, DOX treated, RR treated, and 
combination of DOX and RR treated PC12 neuronal cells.  Although majority of the 
sample sets showed methylation signals for DOX treated and combination treated PC12 
neuronal cells, there were exceptions that did not show any methylation signals (only 
showed unmethylation signals).  This is probably also due to the variability of maturation 
stages of PC12 samples from different days, the transient nature of immediate early gene 
induction that is not easily captured, and the sensitive limit of MSP (Tischmeyer & 
Grimm, 1999; Hughes & Dragunow, 1995; Herrera & Robertson, 1996). 
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CHAPTER FIVE   CONCLUSIONS & FUTURE WORK 
This chapter includes conclusions and future work of this dissertation.  The section 
of conclusions summarizes the results and accomplishments of this dissertation research. 
The section of future work focuses on identifying areas of research that this dissertation 
can possibly lead to.  
 
5.1 Conclusions 
This dissertation is the first contribution to show the effects of in vitro digested and 
in vivo human metabolized RR on DOX chemotherapy induced neurotoxicity in NGF 
induced PC12 neuronal cells, and to suggest epigenetic DNA methylation changes are 
associated with this process.  A better understanding of neurotoxicity of DOX and 
neuroprotection of RR at the cell and epigenetic level has been initiated.  Human plasma 
containing the in vivo metabolized products of RR was used in this work.  This novel 
methodology mimicks the internal environment in the human body showing metabolized 
RR has a potential to protect neurons.  This interdiciplinary study utilizing knowledge 
from cell biology, molecular genetics, epigenetics, medicine, nursing, and nutrition, is a 
representation of bench research in the discipline of healthcare genetics, with the 
potential for translation into the clinical arena.  Major conclusions of this dissertation are 
summarized in the following paragraphs. 
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5.1.1 Effects of Doxorubicin on Metabolic Activity of PC12 Neuronal Cells 
Neurotoxicity associated with chemotherapy has been well documented in both the 
laboratory and clinical settings (Ahles et al., 2002; Brezden et al., 2000; Downie et al., 
2006; Jansen et al., 2010; Schagen et al., 1999; Shilling et al., 2005; Wefel et al., 2004).  
This study specifically looked at effects of DOX chemotherapy on metabolic activity of 
NGF induced PC12 neuronal cells.  It was found that: 1) as minute amount as 0.001µM 
of DOX reduced the metabolic activity of NGF induced PC12 neuronal cells; 2) with the 
increase of concentration of DOX, the metabolic acitivity of NGF induced PC12 neuronal 
cells decreased; and 3) when the concentration of DOX was greater than 1µM, metabolic 
activity of NGF induced PC12 neuronal cells decreased abruptly.  These results indicate 
as small amount as 0.001µM of DOX can potentially cause neurotoxicity.  The 
mechanisms responsible for the neurotoxic effects of DOX can include direct neuronal 
toxicity, secondary neurotoxic metabolites such as inflammatory cytokines that can pass 
the blood-brain barrier, free radical mediated oxidative stress and DNA damage.  The 
mechanism responsible for cell death may have shifted from apoptosis to necrosis around 
1µM of DOX. 
 
5.1.2 Effects of in Vitro Digested Red Raspberry on Doxorubicin Treated PC12 
Neuronal Cells 
This study looked at effects of in vitro digested RR on metabolic activity of PC12 
neuronal cells by MTS assay.  It was found that: 1) in vitro digested RR did not 
statistically affect the metabolic activity of PC12 neuronal cells, although there was a 
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trend of increased metabolic activity for 0.0625% to 0.5% digested raspberry treated cells 
and decreased metabolic activity for over 1%  digested raspberry treated cells; 2) the 
metabolic activity of cells treated with a combination of 0.1% digested RR and 1µM or 
0.1µM of DOX was higher than that of cells treated with DOX alone; 3) with increased 
concentrations of DOX, the differences between metabolic activities of cells treated with 
and without digested raspberry decreased; 4) the cells treated with digested RR had more 
neurite connections compared to control cells treated with DMSO; and 5) the cells treated 
with digested RR plus DOX had more neurite connections compared to cells treated with 
DOX alone.  These results extend the findings showing that berries display neuro-
protective effects in various in vitro and in vivo models of toxicity (Fortalezas et al., 
2010; Joseph et al., 2009;Kang et al., 2006; Shin et al., 2006; Pannangrong et al., 2011; 
Ramiro-Puig et al., 2009).  The mechanisms responsible for the neuro-protective effects 
of RR against DOX chemotherapy likely include the high antioxidant activity, 
involvement in anti-inflammatory/anti-stress signaling pathways, inhibition of apoptotic 
pathways, and genoprotective effect of phenolic compounds in berries (Barros et al., 
2006; Fortalezas et al., 2010; Joseph et al., 2009; Kang et al., 2006; Pangnangrong et al., 
2011; Shin et al., 2006).  The high levels of total phenolic compounds especially 
anthocyanins, ellagic acid, flavonols, and stilbenes in RR may contribute to these 
working mechanisms. 
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5.1.3 Effects of Human Plasma Collected Prior to and After Red Raspberry 
Consumption on Doxorubicin Treated PC12 Neuronal Cells 
Most traditional neurobiological research uses food extracts to treat neuronal cell 
lines to determine the neurotoxicity or neuro-protective effects of the extracts.  However, 
the extracts used were not metabolized in vivo.  This study addresses this methodological 
limitation by using human plasma that contains the in vivo primary and secondary 
metabolic products of RR, mimicking the internal environment in the human body rather 
than using in vitro digested RR alone.  Post-plasma of participants #1-#4 showed a neuro-
protective effect against DOX chemotherapy, while post-plasma of participants #5 & #6 
did not show such effect.  The protective index of post-plasma for six participants is 
higher than that of pre-plasma with no statistical significance.  These individual 
variations could be caused by any difference in the metabolic system such as microflora, 
by genetic differences or other external factors such as diet (Mountzouris et al., 2007; 
Rezzi et al., 2007).  The metabolized products that have a high level of bioavailabiliy and 
bioactivity and account for the neuroprotective effects of  RR are not clear. Phenolics 
such as Anthocyanins are candidates under research. 
 
5.1.4 Effects of Doxorubicin, in Vitro Digested Red Raspberry, and Combination 
on DNA Methylation of PC12 Neuronal Cells 
Many studies have linked epigenetic mechanisms to neuronal/cognitive functions 
postulating that transient reprogramming of epigenetic codes such as DNA methylation 
and histone modifications is required for some basic neuronal/cognitive functions such as 
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neuron growth or memory formation (Feng et al., 2010; Levenson et al., 2006; Miller & 
Sweatt, 2007; Lubin et al., 2008; Korzus, 2010; Korzus et al., 2004; Miller et al., 2008).  
This study looked at the methylation pattern of EGR1 gene, BDNF gene and FOS gene of 
the control, DOX treated, RR treated and combination treated PC12 neuronal cells by 
MSP.  Results showed that: 1) the methylation pattern of EGR1 and BDNF stays the same 
for DNA of the control, DOX treated, digested RR treated, and combination treated PC12 
neuronal cells; and 2) majority of the screened sample sets showed a difference in the 
methylation pattern of FOS for DNA from both DOX treated and combination treated 
PC12 neuronal cells compared to control and RR treated cells.  Unmethylation of genes 
usually, although not necessarily, leads to gene expression and gene products. High 
density of methylation usually leads to reduction of transcriptional activity (Ebinger et 
al., 2004).   
 
5.2 Future Work 
While this dissertation reveals some interesting phenomena in neuronal function and 
epigenetics in vitro, there are still many questions to investigate.  To enhance 
understanding of the neuro-protective effects of RR, the underlying mechanisms, and 
determine its clinical application, the recommended future studies are summarized as 
follows: 
1) A primary neuronal cell line is needed in future research to replace PC12 neuronal 
cell line. PC12 neuronal cell line is derived from a pheochromocytoma of the rat 
adrenal medulla. Embryologically, adrenal medulla cells and postganglionic 
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neurons are developed from the same progenitors (Greene, 1982). When grown in 
vitro, in the presence of NGF, the adrenal cells exhibit neuronal behavior. The 
PC12 cell line is easier to manipulate in the lab than primary neuronal cell lines 
and is considered a standard cell model for neuron study (Alder et al., 2006). 
However, NGF induced PC12 neuronal cells only develop neurites but not 
synapses. From this point of view, a primary neuron cell line should be a good 
choice to further this study. Comparison of results from the primary cell line and 
PC12 cell line should offer more information on the differences between cell lines 
and provide basis for future similar neurotoxicity research. 
2) Neurite outgrowth is a fundamental process in neuronal development and a good 
indicator of neuron function. It is expected that the introduction of more accurate 
parameters for neurite growth, such as total length, maximum length, root count, 
extremities count, node points and segment count etc., should help improve the 
prediction accuracy. Also, advanced analysis platforms and software with an 
algorithm that analyzes fluorescent images is expected to better characterize fine 
and complex neuronal structures in further study. 
3) Some interesting observations of effects of RR on DOX treated PC12 neuronal 
cells have been observed, but further work is needed to enhance understanding of 
these phenomena, especially from cellular and molecular perspective. The 
components in RR that work as neuro-protective contents after human 
metabolism, and the pathways through which these components work remain to 
be revealed in future research. 
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4) Interesting results in DNA methylation changes induced by DOX chemotherapy 
have been observed by methylation specific PCR. Further experimental and/or 
analytical research is expected to better elucidate the process. The future work 
may focus on looking at DNA methylation of other genes, quantifying the amount 
of DNA methylation, and investigating other epigenetic mechanisms especially 
histone acetylation. Synchronizing cells before measurement should help to 
improve the accuracy of results. 
5) The goal of studying the effect of DOX on neuronal cells is to prevent 
neurotoxicity of DOX.  Understanding the underlying biological pathways that 
account for the neuronal toxic effects of DOX should help design right-to-target 
preventions in order to achieve this goal.  This dissertation suggests DOX can 
induce apoptosis or necrosis, or both at different ranges of concentrations, 
indicating there are possibly more than one pathway involved in neurotoxicity of 
DOX.  Fully understanding how chemical messengers deregulated in cancer 
patients, such as inflammatory cytokines and estrogens, are involved in these 
pathways may help maximize anti-cancer effects and minimize side effects of 
DOX administration. In addition, this dissertation showed DNA methylation 
status of DOX treated PC12 neuronal cells was different from the control cells. 
Therefore, further study can also focus on exploring how DOX initiates the DNA 
methylation changes and how these changes are involved in cell death pathways. 
6) Promising results have been observed in this study in vitro and in vivo. In order to 
achieve the ultimate goal of this study to use RR as a natural intervention to 
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prevent cognitive impairments of cancer patients receiving DOX chemotherapy, a 
preliminary clinical research needs to be conducted. Key research activities 
should include evaluating cognitive performance of cancer patients receiving 
DOX chemotherapy, evaluating the effect of natural RR on cognitive performance 
of cancer patients receiving DOX chemotherapy, and exploring the epigenetic 
changes and other biological pathways associated with this process. The 
investigation of underlying pathways can be done using neuronal cell lines treated 
with blood plasma that contains DOX chemotherapy in vivo metabolized by 
cancer patients. The changes of biological parameters in blood plasma and plasma 
treated neurons can be correlated with changes of cognitive performance for each 
participant. Appendix A describes a possible preliminary clinical research plan. In 
the future study, it is important to explore the potential benefits as well as possible 
side/toxic effects in order to throughly understand how an natural intervention, 
such as RR intake for prevention of chemotherapy induced cognitive 
impairments, can be personalized. 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APPENDICES  
Appendix A   Plan for preliminary clinical research 
 (i) Participant plan and description 
By power analysis of G*Power 3.0.10, group sample size of N = 25 is required to 
provide 80% power (p < 0.05) to detect a mean difference of 0.25 (σ = 0.50) with effect 
size 0.6 for paired t-test.  Group sample size of N = 26 is required to provide 80% power 
(p < 0.05) to detect a mean difference of 0.25 (σ = 0.50) with effect size 0.8 for unpaired 
t-test.  An additional 20% will be added to account for attrition. Therefore, the planned 
sample size is ≥30 participants.  However, for a preliminary clinical research, 10-20 per 
group should be acceptable.  
Patients will be recruited from a hospital setting.  Women diagnosed with Stage I-II 
breast cancer will be invited to participate by a designated study researcher if inclusion 
and exclusion criteria are met.  After the women agree to participate, an investigator will 
contact them, explain the study procedures and obtain written informed consent. 
 
Inclusion Criteria 
•Post-menopausal female 
•ER+/PR+ and HER2/neu - 
•Stage I-II breast cancer 
•Chemotherapy 
•Consensus Lumpectomy status 
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Exclusion Criteria 
•History of head injury 
•Evidence of delirium, dementia, aphasia 
•A previous diagnosed psychiatric illness 
•Alcohol or drug abuse 
•Central nervous disease 
•A previous malignancy 
•Previous chemotherapy 
•Current cortisol medication 
•Current medication involving methyl group 
•History of allergy to RR, tomato-based foods, jams, licorice, thyme, dill and chestnuts. 
 
(ii) Overview of methods/implementation (i.e., procedures for data collection, 
interventions, measures) 
Participants will be randomly assigned to two groups: control group and treatment 
group. 
1) Participants in control group will be given a battery of cognitive tests described 
later, and a 4*7ml blood draw pre-chemotherapy treatment at week 1, the end of the first 
cycle of chemotherapy at week 4, the end of third cycle at week 10, 4 weeks post-
treatment at week 23. (Figure Appendix A.1). 
2) Participants in treatment group will be given an additional cognitive test and 
blood draw pre-raspberry treatment at week 0.  In addition, they will be asked to eat two 
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cups of freeze-dried RR per day for 3.5 days before chemotherapy, with half being 
ingested in the morning and half in the evening.  On the fourth day, participants will be 
asked to eat one cup of berries in the morning, (for a total of 3.5 days of berry intake) and 
return to clinic 2-4 hours after the last berry consumption to have their cognitive test, 
blood draw and chemotherapy (Figure Appendix A.1). 
After each blood draw, the plasma will be separated from the blood and frozen for 
later analysis. Levels of estrodiol, progesterone, cortisol, and cytokines IL-1β, IL-6 and 
TNF-α in blood plasma will be measured.  The plasma will be also added to the 
experimental medium to maintain the PC12 neuronal cell line for neuronal metabolic 
activity measurements. 
The changes of biological parameters in blood plasma and plasma treated neurons 
will be correlated with changes of cognitive performance for each participant. 
Cognitive tests include the stroop test, the memory span test, and the levels of 
processing test.  The Stroop Test is a valid and reliable test to measure the executive 
function and inhibitory control of participants.  The test requires participants to name the 
ink color that the words are printed in, which may be the same or different from the color 
that the words (such as yellow, blue, black) indicate.  The score for Stroop Test can be 
adjusted by participant’s age and educational level, with higher scores indicating better 
cognitive function. 
The Memory Span test is a robust test to measure working memory of participants. 
One each trial, you see a list of items presented one at a time in a random order and are 
asked to recall the items in the same order in which they are presented.  If you get a list 
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correct, the list length increases by 1 for that type of material. If you get a list incorrect, 
the list length decreases by 1.  The independence variable is the type of material you were 
asked to recall: digits, letters that sound dissimilar, letters that sound similar, short words, 
and long words.  The dependent variable is the list length of the last list you correctly 
recalled. 
Levels of Processing test is a reliable and robust test to measure semantic memory 
and episodic memory of participants.  There are two parts to this experiment.  In Phase I, 
you are given a word and a judgment task.  In Phase II, you see a series of words, half of 
which have been shown in Phase I.  For each word, you were asked to indicate if it had 
been shown in Phase I.  The logic of the test is that Phase I tests the words in your 
semantic memory, and if you can remember which words were presented in the first test 
section, that means you can remember what happened to you in the past, thus you can 
retrieval from your episodic memory. 
Participants will be given these cognitive tests pre-raspberry treatment at week 0 (if 
they are in treatment group), pre-chemotherapy at week 1, the end of the first cycle of 
chemotherapy at week 4, the end of third cycle at week 10, 4 weeks post-treatment at 
week 23. (Figure Appendix A.1). 
4*7ml vials of whole blood will be collected for each participant using green top 
tubes from BD (Franklin Lakes, NJ) and transported for centrifuging within 4 hours.  
Tubes containing heparin will be inverted 8 to 10 times after collection to ensure 
thorough mixing of the lithium heparin with the blood and, therefore, complete 
anticoagulation of the sample. 
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The tubes with the separation gels will be centrifuged for 10 mins at 1000 - 1300 
RCF (g-force) in swinging bucket rotor to separate into plasma and red blood cell layers.  
The tubes will be removed from the centrifuge, and opened in a clean and safe 
environment to access the plasma located at the top of the specimen.  Using a sterile 
transfer pipet or a 1000 µl pipettor, the plasma will be carefully transferred into 
appropriately labeled amber screw-cap microcentrifuge tubes.  As soon as possible, the 
collected plasma will be placed and stored at -80°. 
It is important to minimize the contact of plasma with blood cells, plasma left in 
room temperature (should be -80°C) and freeze thaw cycle (should be ≤ 2) during this 
process.  Blood and plasma will be transported in an approved biohazard container. 
Labeled frozen plasma samples will be evaluated for levels of estradiol, cortisol and 
progesterone and cytokines IL-1β, IL-6 and TNF-α. 
 
(iii) Statistical analyses if applicable and/or methods of evaluation of the goals, 
objectives, and outcomes of the proposed project 
Statistical analyses will be performed using the Statistical Package for the Social 
Sciences (SPSS/PASW) Version 18.0.  Descriptive statistics and frequency distributions 
will be generated for demographic, disease and treatment characteristics.  T-test will be 
used to test the differences of biological indicators between neurons treated with plasma 
from control group and treatment group.  The significance levels will be set at .05 for all 
analyses.  Linear Regression will be used to evaluate the trajectory of cognitive function 
and biological indicators over time.  For subsequent analyses, ANOVA will be used to 
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look at the correlation between neuronal function changes measured in vitro and 
cognitive performance changes of breast cancer patients in clinical setting. 
 
(iv) Expected outcomes 
It is expected that the in vitro digested RR can protect PC12 neuronal cells from 
detrimental alterations caused by in vivo metabolized DOX chemotherapy. It is also 
expected that neuron metabolic activity, oxidative stress, cytokine levels, estrogen & 
cortisol hormone levels, and epigenetic DNA methylation are associated with this 
process. 
 
(v) Potential problems and alternative strategies if something does not go as 
planned 
If participant recruitment takes longer than expected, or participant number cannot 
reach the number originally planned, alternative strategies may include selecting multiple 
research sites, loosening inclusion criteria, and recruiting patients with other cancers 
besides breast cancer who are being treated with DOX chemotherapy. 
 
 73 
 74 
Appendix B   Lab Protocols 
 
Collagen Coating Protocol: 
1. Prepare 0.1N acetic acid (AA) by adding 1.15ml of 17.4N AA to 198.85ml 
Double Distilled (DD) water. 
2. Add 3.2mg collagen to 3.2ml of 0.1N AA to prepare 1mg/ml solution. Dissolve 
by gentle shaking. 
3. Add 150µl of 1 mg/ml collagen to 2850 µl 1*PBS (sterile) to prepare .05mg/ml 
solution. 
4. Add 33 µl of solution from step 3 to each well   (well size: 0.28cm2, 0.2 ml) if 
using plates. 
5. Add 450 µl of solution from step 3 to each flask if using flasks. 
6. Refrigerate at 4 °C for no longer than 3 weeks’ storage. 
 
Red Raspberry Digestion Protocol: 
1. Add 10mL of RR to a 50mL conical tube 
2. Adjust pH to 2.8 with 6N HCl 
3. Add 0.5 ml of Pepsin Suspension (4g/L pepsin in 0.1 N HCl) 
4. Incubate at 37°C with shaking for 2 hrs 
5. Adjust pH to 5.7 with 1 N NaOH 
6. Add 2.5 ml of Pancreatic Bile Salts [0.2g Pancreatin and 1.2 g Bile Salts in 100 
ml of 0.1 M NaHCO3 (sodium bicarbonate)] solution to each tube 
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7. Incubate at 37°C with shaking for 2 hrs 
8. Centrifuge tubes for 10 min at 4,500 rpm (~ 3500 g) 
9. Transfer supernatant to 15 mL conical and store at 4°C refrigerator 
10. Filter sterilize approximately 3 mL of supernatant into sterile culture tube by 
passage through 2µ syringe filter 
11. Use for treatment of cells or store at 4°C refrigerator 
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Appendix C   IRB Approval 
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Table 2.1 
Designed primers for methylation specific PCR 
Gene Primers Product size 
EGR1/Zif 268 
LM: AGATTTTTGAAATAGAGGTCGATTC 
RM: AACTAAAACAAAAACCGATCTTACG 
LU: TAGATTTTTGAAATAGAGGTTGATTTG 
RU: AAACTAAAACAAAAACCAATCTTACAAC 
M: 129 bp 
U: 131 bp 
GR/NR3C1 
LM: TTTTAGTTTTTTTTGGTAGAGACGA 
RM: CACATTACTTATAAAACCTTTCGAA 
LU: TTTTAGTTTTTTTTGGTAGAGATGA 
RU: CACATTACTTATAAAACCTTTCAAA 
M: 206 bp 
U: 206 bp 
BDNF 
LM: CGGAAAGTATTAGAGGTAGGGTAGC 
RM: TATATACAACTAAATCCGCCCTACG 
LU: TTGGAAAGTATTAGAGGTAGGGTAGTG 
RU: TATACAACTAAATCCACCCTACAAA 
M: 147 bp 
U: 146 bp 
FOS 
LM: TAATTGAGAAGATTGGATAGAGTCG 
RM: CGCTACTACAACGAAAAAATAACG 
LU: AGTAATTGAGAAGATTGGATAGAGTTG 
RU: CACTACTACAACAAAAAAATAACACC 
M: 190 bp 
U: 192 bp 
CREB 
LM: GTTTTTTTAGAACGGGTTTTAATTC 
RM: AATACCGAATACGCAACGAC 
M: 181 bp 
U: 182 bp 
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LU: TTTTTTAGAATGGGTTTTAATTTGT 
RU: CCCAATACCAAATACACAACAAC 
TNF 
LM: TTTCGGATTTATTTTTACGATTATC 
RM: AAACTCAAAACTATCCCTTCGAC 
LU: TTGGATTTATTTTTATGATTATTGA 
RU: CAAACTCAAAACTATCCCTTCAAC 
M: 223 bp 
U: 222 bp 
Tp53 
LM: AATTGGTTTTGGTGAAAAATTATAC 
RM: AAAAAATAAAAACTAAATAATAAATATCGA 
LU: TTGGTTTTGGTGAAAAATTATATGA 
RU: TAAAAAATAAAAACTAAATAATAAATATCA 
M: 262 bp 
U: 259 bp 
Notes: These primers were used in MSP, and the bolded primers were the primers worked in 
MSP. L: Left; R: Right; M: Methylated; U: Unmethylated; EGR1: Early Growth Response 1; GR: 
Glucocorticoid Receptor; BDNF: Brain-derived Neurotrophic Factor; CREB: cAMP response 
element-binding; TNF: Tumor necrosis factor. 
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Table 3.1 
Data for metabolic activity of doxorubicin treated PC12 neuronal cells 
Notes: The metabolic activities of PC12 neuronal cells treated with various concentrations of 
DOX were all statistically different from the DMSO control.  The results indicate minute amounts 
of DOX reduced the metabolic activity of PC12 neuronal cells, exibiting neurotoxicity.  Data 
were compared by two-tail Student t-test with p < 0.05 considered statistically significant.  
 
Average 
Metabolic 
Activity 
Standard 
Error 
p-value 
DMSO control 1 0      
DOX 0.001µM 0.869 0.035 0.032     
DOX 0.01µM 0.715 0.068 0.025 0.036    
DOX 0.1µM 0.595 0.117 0.041 0.045 0.205   
DOX 1µM 0.537 0.103 0.020 0.017 0.035 0.161  
DOX 10µM 0.357 0.071 0.003 0.001 0.0004 0.026 0.0168 
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Table 3.2 
Data for metabolic activity of in vitro digested red raspberry treated PC12 neuronal cells 
Notes: Compared to control, metabolic activity of 0.0625% to 0.5% digested RR treated PC12 
neuronal cells increased and metabolic activity of 1% of in vitro digested RR treated cells 
decreased without statistical significance.  The results indicate 0.0625% to 0.5% in vitro digested 
RR have the potential to promote metabolic activity of PC12 neuronal cells.  Data were compared 
by two-tail Student t-test with p < 0.05 considered statistically significant. 
 
 
Average Metabolic 
Activity 
Standard Error p-value 
Water control 1 0  
RR 0.0625% 1.136 0.079 
0.146 
RR 0.125% 1.138 0.0677 0.097 
RR 0.25% 1.068 0.0811 0.440 
RR 0.5% 1.041 0.0543 0.483 
RR 1% 0.819 0.0893 0.098 
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Table 3.3 
Data for metabolic activity of doxorubicin plus in vitro digested red raspberry treated PC12 
neuronal cells 
Notes: The metabolic activity of PC12 neuronal cells treated with combinations of in vitro 
digested RR and DOX were higher compared to that of cells treated with DOX alone (p = 0.035 
& 0.057).  The results indicate in vitro digested RR counteracted the neuro-toxic effect of low 
concentrations of DOX on metabolic activity of PC12 neuronal cells.  Data were compared by 
two-tail Student t-test with p < 0.05 considered statistically significant. 
 
 
 
 
 
 
 
 
 
 RR 0% RR 0.1% p-value 
DOX 0M 1 1.232±0.061 0.013 
DOX 0.1µM 0.966±0.088 1.178±0.024 0.035 
DOX 1µM 0.897±0.080 1.088±0.023 0.057 
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Table 3.4 
Methylation patterns of BDNF, EGR1 and FOS genes for DNA from the control and treated 
PC12 neuronal cells 
Notes: The methylation patterns of EGR1 and BDNF were the same for DNA of control, DOX 
treated, digested RR treated, and combination treated PC12 neuronal cells; methylation pattern of 
FOS changed for DNA of DOX and combination treated PC12 neuronal cells compared to control 
and in vitro digested RR treated cells.  The results indicate treatments did not change the 
methylation pattern of EGR1 and BDNF genes, but changed the methylation pattern of FOS gene. 
Black shade: Strong band in gel electrophoresis; Grey shade: Weak band in gel electrophoresis; 
White shade: No band in gel electrophoresis; Control: DNA of control PC12 neuronal cells; 
DOX: DNA of DOX treated PC12 neuronal cells; RR: DNA of in vitro digested RR treated PC12 
neuronal cells; DOX+RR: DNA of PC12 neuronal cells treated with DOX plus in vitro digested 
RR.  
 
Primers Control DOX RR DOX + RR 
EGR1_U     
EGR1_M     
BDNF_U     
BDNF_M     
FOS_U     
FOS_M     
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Table 3.5 
Screening of methylation pattern of FOS gene for DNA from the control and treated PC12 
neuronal cells 
Notes: A majority of the screened sample sets showed a difference in the methylation pattern of 
FOS gene for DNA from DOX treated and combination treated PC12 neuronal cells.  The results 
indicate DOX treatment may have induced FOS gene methylation, while in vitro digested RR did 
not reverse this effect.  *: Band in gel electrophoresis; M: Methylated; U: Unmethylated; Control: 
DNA of control PC12 neuronal cells; DOX: DNA of DOX treated PC12 neuronal cells; RR: 
DNA of in vitro digested RR treated PC12 neuronal cells; DOX+RR: DNA of PC12 neuronal 
cells treated with DOX plus in vitro digested RR. 
  Control RR DOX DOX + RR 
FOS_M Feb 25th sample     
 Mar 4th sample   * * * 
 Mar 9th sample   * * 
 Apr 5th sample     
 Apr 23rd sample   * * 
 Jun 14th sample     
 Jun 20th sample   * * 
FOS_U Feb 25th sample * * * * 
 Mar 4th sample  * * * * 
 Mar 9th sample * * * * 
 Apr 5th sample * * * * 
 Apr 23rd sample * * * * 
 Jun 14th sample * * * * 
 Jun 20th sample * * * * 
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Table 4.1 
Genes and functions of gene products 
Genes  Functions of Gene Products 
EGR1/Zif 268 
Transcriptional factor; Required for memory formation, differentiation 
and mitogenesis (Bozon et al., 2002; Jones et al., 2001) 
GR/NR3C1 
Transcriptional factor; Inflammatory/Stress response; Cellular 
proliferation & differentiation (Lu & Cidlowski, 2004; Barnes, 1998; 
Sapolsky, Romero, & Munck , 2000) 
BDNF 
Transcriptional factor; Support the survival of existing neurons, encourage 
neurite outgrowth and cell plasticity (Aid et al., 2007) 
TNF 
Cytokine in inflammation; Regulation of immune cells  
(Pfeffer, 2003) 
TP53 DNA repair and apoptosis (Bai & Zhu, 2006) 
CREB 
Transcriptional factor; Neuronal survival, proliferation and differentiation; 
Formation of long-term memory (Lonze & Ginty, 2002) 
FOS 
Proto-oncogene; immediate early gene family of transcription factors; 
regulates genes involved in proliferation and differentiation to defense 
against invasion and cell damage; Up regulation indicates recent neuronal 
activity (Hu et al., 1994; Kovács, 1998) 
Notes: These genes are frequently targeted in research of cognitive functions, and were tested in 
this study for changes of DNA methylation.  EGR1: Early Growth Response 1; GR: 
Glucocorticoid Receptor; BDNF: Brain-derived Neurotrophic Factor; CREB: cAMP response 
element-binding; TNF: Tumor necrosis factor.
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Figure 1.1. Methylation pathway  
 
 
 
Figure 1.1. A schematic diagram showing folate acid in berries is involved in DNA/histone methylation.  
Adapted from “Aging, cancer and nutrition: The DNA methylation connection,” by L. Lu, R. C. Wylie, L. 
G. Andrews, and T. Q. Tollefshol, 2003, Mechanisms of Ageing and Development, 124, 989-998. 
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Figure 1.2. Mediators and moderators in cancer and chemotherapy induced cognitive decline 
 
  
 
Figure 1.2. A schematic diagram of confounding variables involved in cancer and chemotherapy 
induced neurotoxicity and cognitive decline.  Adapted from “Candidate mechanisms for 
chemotherapy-induced cognitive changes,” by T. A. Ahles and A. J. Saykin, 2007, Cancer, 7, 
192-201. 
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Figure 1.3. DNA methylation and transcription 
 
 
 
Figure 1.3. A schematic diagram of how DNA methylation and unmethylation lead to activation 
and silencing of subsequent genes.  Adapted from “Epigenetics: an overview,” by R. Holiday, 
1994, Developmental Genetics, 15, 453-457. 
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Figure 1.4. Histone acetylation and transcription 
 
 
 
Figure 1.4. A schematic diagram showing how histone acetylation leads to relaxation of 
heterochromatin and promotes gene transcription.  Adapted from “Manipulating the brain with 
epigenetics,” by E. Korus, 2010, Nature Neuroscience, 13, 405-406. 
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Figure 2.1. Experimental design for effects of doxorubicin on metabolic activity of PC12 
neuronal cells 
 
 
 
Figure 2.1. Laboratory procedure for experiment reported in Section 2.1. 
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Figure 2.2. Experimental design for effects of in vitro digested red raspberry on metabolic activity 
of PC12 neuronal cells 
 
 
 
Figure 2.2. Laboratory procedure for experiment reported in Section 2.2. 
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Figure 2.3. Experimental design for effects of in vitro digested red raspberry on metabolic 
activity of doxorubicin treated PC12 neuronal cells 
 
 
 
Figure 2.3. Laboratory procedure for experiment reported in Section 2.3. 
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 Figure 2.4. Experimental design for effects of in vitro digested red raspberry on neurite 
growth of doxorubicin treated PC12 neuronal cells 
 
 
 
Figure 2.4. Laboratory procedure for experiment reported in Section 2.4. 
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 Figure 2.5. Experimental design for effects of human plasma collected prior to and after 
red raspberry consumption on metabolic activity of doxorubicin treated PC12 neuronal 
cells 
 
 
 
Figure 2.5. Laboratory procedure for experiment reported in Section 2.5. 
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 Figure 2.6. Experimental design for effects of doxorubicin, in vitro digested red raspberry, 
and combination on DNA methylation of PC12 neuronal cells 
 
 
 
Figure 2.6. Laboratory procedure for experiment reported in Section 2.6. 
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 Figure 3.1. Metabolic activity of doxorubicin treated PC12 neuronal cells 
 
 
 
Figure 3.1. A bar chart comparison of metabolic activity changes of PC12 neuronal cells caused 
by DOX treatments.  The metabolic activities of PC12 neuronal cells treated with various 
concentrations of DOX were all statistically different from the DMSO control.  The results 
indicated minute amounts of DOX reduced the metabolic activity of PC12 neuronal cells, 
exibiting neurotoxicity.  Data were compared by two-tail Student t-test with p < 0.05 considered 
statistically significant.
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Figure 3.2. Metabolic activity of in vitro digested red raspberry treated PC12 neuronal cells 
 
 
 
Figure 3.2. A bar chart comparison of metabolic activity changes of PC12 neuronal cells caused by in 
vitro digested RR treatments. Compared to control, metabolic activity of 0.0625% to 0.5% digested RR 
treated PC12 neuronal cells increased and metabolic activity of 1% of in vitro digested RR treated cells 
decreased without statistical significance.  The results indicate 0.0625% to 0.5% in vitro digested RR 
have the potential to promote metabolic activity of PC12 neuronal cells.  Data were compared by two-tail 
Student t-test with p < 0.05 considered statistically significant. 
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Figure 3.3. Metabolic activity of in vitro digested red raspberry and doxorubicin treated PC12 
neuronal cells 
 
Figure 3.3. A comparison of metabolic activity changes of PC12 neuronal cells caused by in vitro 
digested RR and DOX treatments.  The metabolic activity of PC12 neuronal cells treated with 
combinations of in vitro digested RR and DOX were higher compared to that of cells treated with 
DOX alone (p = 0.035 & 0.057 respectively).  The results indicate in vitro digested RR 
counteracted the neuro-toxic effect of low concentrations of DOX on metabolic activity of PC12 
neuronal cells.  Data were compared by two-tail Student t-test with p < 0.05 considered 
statistically significant.  
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Figure 3.4. Neurite growth of in vitro digested red raspberry and doxorubicin treated PC12 
neuronal cells 
 
 
 
Figure 3.4. A visual comparison of changes in neurite growth of PC12 neuronal cells caused by in vitro 
digested RR and DOX treatments.  DOX treated cells had less neurite connections compared to DOX plus 
in vitro digested RR treated cells.  The results indicate in vitro digested RR counteracted the neuro-toxic 
effect of low concentrations of DOX on neurite connections of PC12 neuronal cells.  Each picture 
depicted the spot with the greatest number of neurites on the medium for each sample.  The labels of the 
pictures A-F correspond to A-F in Figure 3.3.  A: Water treated cells; B: 0.1% digested RR treated cells; 
C: 0.1µM DOX treated cells; D: 0.1% digested RR plus 0.1µM DOX treated cells; E: 1µM DOX treated 
cells; F: 0.1% digested RR plus 1µM DOX treated cells. 
A B 
E F 
C D 
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Figure 3.5. Cell metabolic activity ratio of 6 participants for pre-plasma and post-plasma 
 
 
Figure 3.5. A bar chart comparison of changes in metabolic activity of PC12 neuronal cells 
treated with plasma of participants prior to and after consumption of RR.  The calculated ratios 
for post-plasma of participants #1-#4 were higher compared to ratios of their pre-plasma, while 
the calculated ratios for post-plasma of participants #5-#6 were lower compared to ratios of their 
pre-plasma.  The average ratio of post-plasma for six participants was higher than that of pre-
plasma.  The results indicate metabolized RR may have the potential to counteract the neuro-toxic 
effect of DOX with varied responses for different individuals. 
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Figure 3.6. Methylation patterns of BDNF, EGR1 and FOS genes for highly methylated rat genomic 
DNA 
 
 
Figure 3.6. Electrophoresis gel results depicting MSP products for highly methylated rat genomic 
DNA, illustrating designed methylated-specific primers for BDNF, EGR1 and FOS genes work in 
MSP.  Unmethylated-specific primers; M: Methylated-specific primers. 
BDNF_U     BDNF_M     EGR1_U     EGR1_M     FOS_U     FOS_M 
                        147bp                               129bp                          190bp                                 
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Figure 3.7. Methylation patterns of BDNF, EGR1 and FOS genes for DNA from PC12 neuronal 
cells 
 
 
Figure 3.7. Electrophoresis gel results depicting MSP products for DNA from PC12 neuronal 
cells, illustrating designed unmethylated-specific primers for BDNF, EGR1 and FOS genes work 
in MSP.  U: Unmethylated-specific primers.
  FOS_U      BDNF_U     EGR1_U 
                               192bp         146bp          131bp 
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Figure 3.8. Methylation pattern of FOS for DNA from PC12 neuronal cells and highly methylated 
rat genomic DNA 
 
 
 
Figure 3.8. Electrophoresis gel results depicting MSP products for DNA from highly methylated 
rat and PC12 neuronal cells, illustrating designed methylated-specific primers and unmethylated-
specific primers for FOS gene work in MSP.  U: Unmethylated-specific primers; M: Methylated-
specific primers.
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Figure 3.9. Repeated methylation pattern of FOS for DNA from the control and treated 
PC12 neuronal cell samples 
 
 
 
Figure 3.9. Electrophoresis gel results depicting MSP products for DNA from control and treated 
PC12 neuronal cells harvested from different days.  DOX and combination treated cells showed 
methylation signals, while control and RR treated cells did not.  The results indicate DOX 
treatment may have induced FOS gene methylation in PC12 neuronal cells, while in vitro 
digested RR did not reverse this effect.  C: DNA of control PC12 neuronal cells; R: DNA of in 
vitro digested RR treated PC12 neuronal cells; D: DNA of DOX treated PC12 neuronal cells; +: 
DNA of PC12 neuronal cells treated with in vitro digested RR plus DOX; C1,R1,D1,+1: Cells 
harvested on March 9th, 2011; C2,R2,D2,+2: Cells harvested on April 23rd, 2011; C3,R3,D3,+3: 
Cells harvested on June 20th, 2011; 
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Figure 3.10. Percentage of DNA samples that show electrophoresis bands for methylated FOS or 
unmethylated FOS in MSP  
 
 
 
Figure 3.10. A bar chart of percentages of the control and treated PC12 neuronal cell samples that 
showed bands in gel electrophoresis.  This chart indicates a majority of sample sets share the 
same DNA methylation pattern of FOS gene.  There were exceptions probably due to the 
variability of maturation stages of PC12 samples from different days, the transient nature of 
immediate early gene induction that is not easily captured, and the sensitive limit of MSP.  M: 
Methylated; U: Unmethylated; Control: DNA of control PC12 neuronal cells; DOX: DNA of 
DOX treated PC12 neuronal cells; RR: DNA of in vitro digested RR treated PC12 neuronal cells; 
DOX+RR: DNA of PC12 neuronal cells treated with DOX plus in vitro digested RR. 
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Figure 4.1. Apoptosis induced by doxorubicin 
 
 
 
Figure 4.1. A schematic diagram showing DOX induces apoptosis through P53 and Bax in brain 
mitochondria.  Adapted from “ Adriamycin-induced, TNF-α-mediated central nervous system 
toxicity,” by J. Tangpong et al., 2006, Neurobiology of Diseases, 23, 127-139. 
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Figure 4.2. Free radical mediated oxidation induced by doxorubicin 
 
 
Figure 4.2. A schematic diagram showing DOX increases oxidative stress by generating super-
oxide radical O2- which participates in redox cycling.  Adapted from “Prevention of doxorubicin-
induced acute cardiotoxicity by an experimental antioxidant compound,” by P. Deres et al., 2005, 
Journal of Cardiovascular Pharmacology, 45, 36-43.
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Figure 4.3. Cytokine mediated nitration induced by doxorubicin 
 
 
Figure 4.3. A schematic diagram showing DOX induces cytokines to generate oxidative stress.  
Adapted from “Adriamycin-mediated nitration of manganese superoxide dismutase in the central 
nervous system: insight into the mechanism of chemobrain, by J. Tangpong et al., 2007, Journal 
of Neurochemistry, 100, 191-201.
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Figure 4.4. DNA damage induced by doxorubicin 
 
 
 
Figure 4.4. A schematic diagram showing DOX interacts with DNA, helicase and topoisomerase 
II to induce DNA damages.  Adapted from “Structural Comparison of Anticancer Drug-DNA 
complexes: Adriamycin and Daunomycin,” by C. A. Frederick et al., 1990, Biochemistry, 29, 
2538-2549.
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Figure 4.5. Phenolic compounds work through multiple pathways 
 
 
 
Figure 4.5. A schematic diagram illustrating phenolic compounds in RR work through multiple 
pathways to exhibit neuro-protective effects.  Adapted from “Grape juice, berries, and walnuts 
affect brain aging and behavior,” by J. A. Joseph, B. Shukitt-Hale, and L. M. Willis, 2009, The 
Journal of Nutrition, 139, 1813S-1817S. 
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Figure 4.6. Comparision of in vitro digestion and in vivo metabolism 
 
 
Figure 4.6. A schematic comparison of in vitro digestion and in vivo metabolism illustrating the 
use of human plasma containing metabolized RR to treat neuronal cells better mimics what 
happens in the human body.  Adapted from “Bioavailability of various polyphenols from a diet 
containing moderate amounts of berries, by R. Koli et al., 2010, Agricultural and Food 
Chemistry, 58, 3927-3932.
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Figure A.1. A study design for future preliminary clinical research 
 
 
 
 
Figure A.1. A schematic illustration of a study design for future preliminary clinical research. 
 
 
